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Abstract 
FIBROMYALGIA SELF-CARE MANAGEMENT: USE OF ESSENTIAL OILS 
Regina A. Izu, RN; PhD 
Hahn School of Nursing and Health Science 
University of San Diego, San Diego, CA 
Jane Georges, RN; PhD, Advisor 
Fibromyalgia is a female dominant chronic syndrome of diffuse muscle pain 
on palpation of at least 11 of 18 syndrome-associated tender points present for 3 months 
or longer. There is no cure. Self-care management involving multimodal integrative 
medicine approaches may increase treatment involvement resulting in a sense of control 
and pain relief. 
This embedded, single case study explored 'how' and 'why' an informant with 
fibromyalgia chose to initiate and continue self-care management using essential oils 
over several years to treat symptoms within context reality. Orem's Self-Care Deficit 
Model and the Principles of Integrative Medicine from the University of Arizona formed 
the holistic theoretical research frameworks. Mixed methods (descriptive statistics, 
pattern matching and thematic analysis) were used to analyze and triangulate converging 
data from four Likert visual analog scales, rheumatologic medical records, indepth 
interview transcripts, literature reviews, field notes and observations. 
Results indicated that the informant's skills progressed from using pre-mixed 
transdermal essential oils applications to using undiluted, neat, layered transdermal 
interventions of essential oils. Additionally, of the 12 fibromyalgia symptoms treated 
with essential oils, six significantly improved and 5 different symptoms moderately 
improved. Compared to pharmacological measures, self-care management using 
essential oils empowered the informant to more rapidly control her symptoms. 
Quantitative and qualitative data supported internal and external validity and reliability. 
Implications indicated the need for further research in fibromyalgia self-care using 
essential oils to delineate efficacy in symptom management, impact on functional status 
and measurement development. 
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Chapter 1 Introduction and Significance 
Chronic Illness 
One of the most urgent medical challenges in the US is the care of those who live 
with chronic illness or disease (Lawrence, 2005). Chronic conditions "are health prob-
lems that require ongoing management over a period of years or decades" (WHO, 2002, 
p. 11). Chronic illness marginalizes and stigmatizes; ageing is a risk factor (Stuenkel & 
Wong, 2009; WHO). Individuals with chronic illness present antithetical American val-
ues which emphasize youth, attractiveness, independence, and personal accomplishment 
(Stuenkel & Wong). 
Chronic musculoskeletal pain is the number one disability in North America, the 
second most frequent cause of primary care visits; the third most frequent etiology for 
hospitalizations (Ko, Whitmore, Gottfried, Hum, Rahman, Traitses, 2005). Prominent 
within the working population, chronic conditions result in work disabilities, high sick 
absenteeism, early retirement, reduced productivity, poor health outcomes, increasing 
healthcare expenses, decreased or terminated employment, shortened life span, and 
lowered quality of life (QOL) (Henderson, Glozier, & Elliot, 2005; Lewin, 1999; WHO). 
Fibromyalgia 
While many chronic conditions currently impact the health of Americans, fibro-
myalgia (FM) has become one of the most difficult syndromes to manage. A functionally 
disabling chronic condition or syndrome, FM is a female dominant (80% - 90% of cases) 
chronic illness peaking at ages 30 to 50 years and demonstrating an age increasing 
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population prevalence of 2%-13% (Crowther-Radulewicz, 2010; Vierck, 2006; Wolfe, 
Smythe, Yunus, Bennett, Bombardier, Goldenberg, et al, 1990). The American College 
of Rheumatology defines FM as a syndrome of diffuse muscle pain for a minimum of 3 
months duration with pain on palpation of at least 11 of 18 tender points (Crowther-
Radulewicz, 2010; Crowther-Radulewicz & McCance, 2010; Wolfe, et al.). These points 
occur bilaterally on the body. Women with FM experience pain and profound fatigue 
exceeding 90% of their wake time; lowering QOL (Buckwalter & Lappin, 2000). 
Fibromyalgia is a challenge to treat with conventional medicine (Holcraft, Assefi, 
& Buchwald, 2003). Thus, the use of integrative and complementary alternative 
medicine (IM; CAM) in the treatment of FM is an appropriate area of study. Such 
approaches as aromatherapy (AT) utilizing essential oils (EOs) have shown promise in 
reducing symptoms in FM (Ko, Hum, Traitses, 2006; Ough, 2008). 
Self-Care 
The "hidden" health care system is now self-care (Keysor, DeVellis, DeFriese, 
DeVellis, Jordan, Konrad, et al., 2003, p. 724). Patients are in control of important self-
management decisions and can veto health professional recommendations (Glasgow & 
Anderson, 1999). Self-management (SM) and self-care (SC) are interchangeable terms. 
Usually, people self-initiate care activities with the intent to promote health and/or 
manage chronic conditions (DeFriese, Konrad, Woomert, Norburn, & Bernard, 1994; 
Hang, Akiyama, Tryban, Sonoda, & Wykle, 1991; Keysor, et al.; Ory, DeFriese, & 
Duncker, 1998; Holman & Lorig, 1997). Self-care management (SCM) narrates the 
context of human suffering. Daily courage to live with chronic conditions is challenging 
and brings ramifications. 
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Self-management encompasses an individual's ability to manage symptoms, or to 
treat chronic conditions associated with biopsychosocial consequences and lifestyle 
changes (Barlow, Wright, Sheasby, Turner, & Hainsworth, 2002). This implies more 
than simple adherence to treatment guidelines (Hummel, 2009; Newman, Steed, & 
Mulligan, 2004). 
Interventions 
The enduring nature of chronic conditions mandates SC or self-management inter-
ventions (SMIs) as imperative, inevitable, nonoptional behaviors (Bodenheimer, Lorig, 
Holman, & Grumbach, 2002; Cross, 2007). Self-management interventions create a 
process opportunity to increase a person's treatment involvement while bringing control 
and order into their lives (Kralick, Koch, Price, & Howard, 2004; Newman, et al., 2004). 
Care strategies reflect protracted time frames and clarify patient roles and acceptance of 
responsibilities (Newman, et al.; WHO, 2002). 
Individuals with chronic conditions use a variety of techniques to manage symp-
toms and maintain social role normalcy (Larsen, 2009). They process and perceive 
stressors uniquely within their lived context, resulting in either SM, or self-control oppor-
tunities (Delmar, Boje, Dylmer, Forup, Jakobsen, Moller, et al., 2006). More than 400 
published articles provide evidence that interventions promoting patient roles in the man-
agement of chronic conditions lead to improved outcomes (WHO, 2002). Participation in 
decision-making and treatment planning increases efficacy and efficiency (Holman & 
Lorig, 2000). Individuals can choose actions that improve their health. They need 
knowledge, motivation and coping skills to live with chronic conditions (WHO). 
Interventions favor medical technology and pharmacological agents at the ex-
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pense of low-tech strategies, but daily SC health choices are more influential than medi-
cal interventions alone (WHO). The efficacy of SCM encompasses self-monitoring, ef-
fective cognitive, behavioral and emotional responses to maintain QOL (Barlow, et al., 
2002). 
"Prevention and health promotion should be part of every health care encounter, 
but this is far from routine clinical care" (WHO, 2002, p. 34). Health care reimbursement 
is proportionate to volume and cost of delivered services and "punished" for engaging in 
innovative, health promoting clinical practice (WHO). This paradigm shifts from indus-
trial age health care provisions (Cross, 2007) to a challenge for prepared, proactive 
practice teams interacting with informed, activated patients (Bodenheimer, et al, 2002). 
Theoretical Models 
This study modeled a single case study research by Yin (2009). The 8 Principles 
of Integrative Medicine (IM) (Appendix A) originated from the University of Arizona's 
Center for Integrative Medicine (Maizes, Rakel, Niemie, 2009) forming a conceptual 
framework for this research study encompassing both allopathy and CAM. Dorothea 
Orem's (1985) self-care deficit (SCD) model integrated and organized research findings. 
Case Study Research 
Case study research (CSR) designs "are the preferred method when (a) 'how* or 
'why' questions are being posed, (b) the investigator has little control over events, and (c) 
the focus is on contemporary phenomenon within a real-life context" (Yin, 2009, p. 2). 
This common research method in nursing analyzes multiple sources of evidence for data 
convergence in a triangulating fashion (Yin). 
Case study research can include single and multiple-case study designs with a 
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quantitative, qualitative, or mixed method approach (Yin, 2009). Yin identifies 4 distinct 
applications. Most importantly, case studies explain presumed causal links in real-life in-
terventions too complex for survey or experimental designs. Secondly, they describe an 
intervention occurring within real-life context. The boundaries between phenomenon and 
context are not clearly evident. Thirdly, case studies illustrate certain topics within a de-
scriptive evaluation. Finally, case study strategies can enlighten situations in which inter-
ventions are without a clear, single set of outcomes. 
Yin (2009) identifies multiple rationales for using a single CSR design. A single 
CSR design can represent a critical case to test a well-formulated theory. Secondly, it 
can represent an extreme or unique case or thirdly, a representative or typical case. A 
revelatory case can observe and analyze previously inaccessible phenomenon. Two 
variants of the single case study are a holistic design or an embedded unit of analysis. 
Integrative and Complementary Alternative Medicine 
Integrative medicine (IM), a new health care vision, provides a broad patient-
centered paradigm embracing a healing-oriented blend of conventional and complemen-
tary therapies that affirms the importance of therapeutic relationships (Maizes, et al., 
2009). Integrative therapy combines complementary or alternative therapies with 
allopathy (Lewis, de Vedia, Reuer, Schwan, & Tourin, 2003; Rakel, 2007). 
Chronic illness disabilities compel many individuals to complementary alternative 
medicine (CAM) therapies in quest of reducing pain, anxiety, and stress while searching 
for a QOL (Consentino, 2006). "Currently CAM is defined as those medical fields that 
fall outside of conventional medicine" (Maizes, et al., 2009, p. 5). Complementary 
therapies are used in addition to allopathy, or medical approaches taught in accredited 
6 
schools of medicine (Chiappelli, Prolo, Cajulis, 2005; Lewis, et al., 2003). Alternative 
approaches refer to treatments instead of standard medical therapy, or allopathy. 
"The use of CAM by the general population in the US is common, widespread, 
and on the rise" (Kravits & Berenson, 2010, p. 547). The Institute of Medicine (IOM, 
2005) reports that up to one third of US adults use some form of CAM, or 15 million 
adults take herbal remedies and vitamins in addition to drugs. Self-medication is 
becoming more popular using unclear compounds and uncontrolled doses (Nehr, 
Gstottner, Thaurer, Augustijns, Reinelt, & Schobersberger, 2008). Many CAM research 
studies demonstrate methodological flaws (Holdcraft, et al, 2003) making it difficult to 
identify best CAM practices. To summarize, CAM is highly prevalent in the US 
allowing individuals some control or expression but in serious illness, CAM patients 
continue to seek standard medical care (Lewis, et. al., 2003). 
The National Institutes of Health (NIH) initiated attention to CAM research in 
1993 becoming the National Center for CAM [NCCAM] by 2006 (Rakel, 2007). The 
NCCAM classifies therapies into 5 domains including: alternative medical systems; 
mind-body interventions; biologically-based therapies; manipulative and body-based 
therapies; and energy therapies. Aromatherapy is biologically-based since it uses 
substances found in nature (Consentino, 2006, p. 121). 
Aromatherapy 
Aromatherapy (AT) identifies the need to treat mind, body and soul together (Lis-
Balchin, 2006) and is divided into 3 overlapping sciences. They include AT, aromatology 
and aromachology. "Clinical aromatherapy is the therapeutic use of essential oils, the 
efficacy of which is supported by research data" (Buckle, 2001, p. 124). 
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Essential Oils 
Essential oils (EOs) are considered mankind's first medicines. Historically, they 
are described in Egypt, Babylon, China, India, Greece, Rome, and Arabia for physical 
and spiritual health (Lewis, et al., 2003; Smith, 2003). These aromatic volatile liquids are 
a plant's immunity distilled as extracts from shrubs, flowers, stems, branches, bark, roots, 
bushes, leaves, needles, fruits, and seeds; produced in practically every country of the 
world {Essential Oils Pocket Reference fEOPRJ), 2004; Halm, 2008; Helms, 2006; 
Lewis, et al.; Stewart, 2005; Worwood, 1996). 
Essential oils promote healing, are non-toxic, and harmless to human tissue 
demonstrating a long history of safe traditional use when properly administrated (Duning, 
2005, Fischer-Rizzi, 1990; Rose, 2006; Stewart, 2003, 2005). Stewart (2003) identifies 6 
ways that EOs support people as antimicrobials, antioxidants, balances bodily functions 
and emotions, raises bodily frequencies, and increases our spiritual awareness (p. 34). 
Growing evidence supports their use in nursing care (Dunning). Research supporting 
EOs' efficacy claims for clinical implementation in various clinical situations is 
unavailable or highly flawed, yet combined with observations, aromatherapy warrants 
further study (Buckle, 1993; Lewis, et a l , 2003; Spencer & Jacobs, 1999). 
Nursing and Self-Care Deficit 
Nursing signifies the care of "sick and well persons" in hospitals or homes 
(Nightingale, 1859). Orem's (1985) self-care deficit (SCD) theory describes nursing 
agency as the interface to self-care agency. Nursing is complex, compound actions. 
Nursing equates to knowledge; poor nursing, or a lack of nursing, results in symptoms 
and suffering. 
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Orem (1985, p. 15) claims 4 propositions to express facts or beliefs of nursing. 
Nursing is deliberate action, a function of the practical intelligence of nurses. Nursing 
action brings about humanely desirable conditions of persons and their environments. 
Nursing focuses on human beings and their relation to the living reality of persons 
including their function within environmental situations. 
A nurse's role encompasses both art and science. Nursing art involves skill, prac-
tical intelligence and creative care design for individuals or groups under unique, prevail-
ing or changing conditions and circumstances such as chronic conditions, symptoms, and 
illnesses. Nursing science synthesizes knowledge to create new solutions to problems 
within the individual's environment and the challenges within their lived context. Nurses 
provide care for others who are partially or completely unable to meet their SC requisites 
through the vehicle of their specialized knowledge base. Individuals make SC decisions 
based on their knowledge, culture, values, age, and maturity within the context of their 
lived experience. 
Little focus is given, however, to the real clinical potential of EO (Buckle, 2007) 
within the lived context of FM. Nurses need to consider the possibility of integrating or 
facilitating complementary therapies into their practice. Nursing research is the platform 
for an appropriate knowledge base (Norton, 1995). There is great potential for 
collaborative research to explore clinical applications moving beyond low dose 
application paradigms. 
Aim and Purpose 
This was a single case, embedded study. The global aim of this evaluative, 
descriptive research was to explain presumed causal links in the SC use of EOs over 
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several years' usage to mitigate chronic symptoms associated with FM within the real life 
context of an individual. 
The purpose of this study was to explore "how" and "why" the informant chose to 
initiate and continue the SC interventions of EOs over several years. The study included 
how and why an individual self-manages chronic symptoms through several years of 
lived experience; how and why this SC choice maintains function and activities of daily 
living; how and why EOs manage chronic symptoms as well as how the lived experience 
integrated their use and outcomes. Also, since minimal measures existed to collect data 
related to AT, Likert scales were designed, utilized and collected. 
Research Purpose and Questions 
Yin's (2009) single case study research (CSR) embedded method design framed 
the study. The overall purpose of this evaluative, descriptive research was to explore 
proposed causal links in the SC use of EOs over several years of use to mitigate chronic 
symptoms associated with FM within context reality. This study was completed to 
establish the feasibility and efficacy of EOs in the SCM of a middle aged woman with 
FM. It established a baseline for further research studies. 
The specific aims of this single, embedded CSR explored 'how' and 'why' the 
informant, who suffered from FM, chose to initiate SC with EOs and continue this 
regimen over several years. This study addressed the following questions: 
1. How and why did the informant use essential oils in self-care? 
2. How and why did the informant self-manage chronic symptoms of fibromyalgia 
using other aspects of integrative medicine besides essential oils? 
3. How and why did essential oil self-management intervention help the informant 
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maintain function and activities of daily living? 
4. How did the informant integrate self-care management with essential oils, their 
use, effects, and outcomes into the context of her daily life? 
Chapter Two, the background and literature review, presents details regarding the 
theoretical models, fibromyalgia, self-care, integrative and complementary alternative 
medicine, aromatherapy and essential oils as a specific therapeutic intervention. 
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Chapter Two Background and Literature Review 
The purpose of this study was to explore "how" and "why" the informant chose to 
initiate and continue the self-care intervention (SCI) of essential oils (EOs) over several 
years. The study included how and why an individual self-managed chronic symptoms 
through several years of lived experience; how and why this self-care (SC) choice main-
tained function and activities of daily living (ADL); how and why EOs managed chronic 
symptoms as well as how the lived experience integrates their use and outcomes. 
Literature Review 
The review of literature provided a summary of the relevant literature informing 
this study. Specifically, it described the organizing theoretical model, the Self Care 
Deficit Model of Orem (1985). The following major concepts were also explored in this 
study: 1) self-care; 2) fibromyalgia and its attendant distressing symptoms; 3) integrative 
and complementary alternative medicine; 4) aromatherapy; 5) essential oils as a specific 
therapeutic intervention. 
Organizing Theoretical Models 
The Principles of Integrative Medicine from the University of Arizona provided 
an umbrella conceptual framework (Maizes, et al., 2009) to discuss aromatherapy (AT) 
and EOs. This study followed the case study research (CSR) work of Yin (2009). 
Dorothea Orem's (1985) self-care deficit (SCD) model permeated and integrated the 
chain of evidence within the study. 
Integrative and Complementary Alternative Medicine 
Integrative medicine (IM), a new health care vision, provides a broad patient-
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centered paradigm embracing healing-oriented therapies (Maizes, et al., 2009). Within 
the IM paradigm, allopathy (traditional, conventional medicine) and complementary and 
alternative therapies (CAM) coexist and affirm the importance of therapeutic relation-
ships (Lewis, et al., 2003; Maizes, et al., 2009; Rakel, 2007). Large numbers of CAM 
therapies are available and controversial anecdotal stories prevail amidst research paucity 
(Kravits & Berenson, 2010). 
Searching for quality of life (QOL) in a world of noncurative treatment, chroni-
cally ill individuals try CAM therapies in quest of symptom palliation to reduce pain, 
anxiety, and stress (Consentino, 2006; Kravits & Berenson, 2010). High rates of CAM 
interventions occur in those suffering from rheumatologic disorders like fibromyalgia 
(FM) which offers unsatisfactory, noncurative treatment options (Holdcraft, et al., 2003). 
Reasons individuals choose CAM therapies include the reduction of disease, treatment of 
side effects, improvement of overall health and immune system, easier access to care 
with less expense than conventional medicine and the hope of altering disease 
progression (Kravits & Berenson). 
In 2004, Jokic, a researcher at The University of Toronto, completed a community 
CAM survey during an education session attended by 72 FM participants. The most 
common products tried did not mention EO but included topical rubs, sleeping pills, and 
transcutaneous electrical nerve stimulation (66.7%), braces and orthotics (58.3%), diets 
and over the counter (OTC) oral (PO) medications (54.2%), glucosamine, herbals, 
megavitamins (50%), magnets (37.5%), and opioids (41.7%). The most common CAM 
practitioners or therapists utilized by the FM participants included massage (75%), 
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meditation/relaxation and acupuncture (70.8%), chiropractic (58.3%), 
homeopathy/naturopathy (41.7%), and spiritual healing/prayer (37.5%). 
Case Study Research 
This study models the work of Yin (2009), who proposed the use of a specific ap-
proach to CSR as appropriate in the applied social sciences. According to Yin's model, 
CSR designs are preferred when 'how' or 'why' questions are posed, if the focus is on 
real-life contemporary phenomenon or when the investigator has little control over 
events. This method analyzes multiple data sources of evidence convergence in a 
triangulating fashion. 
Case study research includes single or multiple-case study designs with a 
quantitative, qualitative, or mixed method approach (Yin, 2009). Yin identifies 4 distinct 
CSR applications. Most importantly, case studies explain presumed causal links in real-
life interventions too complex for survey or experimental designs. Secondly, they 
describe an intervenvention occurring within real-life context when boundaries between 
phenomenon and context are unclear. Thirdly, CSR illustrates topics within a descriptive 
evaluation. Finally, CSR strategies can enlighten situations when interventions are with-
out clear, singular outcomes. In Yin's approach, the investigator utilizes a theoretical 
framework that examines the "logic linking the data to the propositions" (Yin 2009, pg. 
27). For the purpose of this study, nurse scientist Dorothea Orem's (1985) Self-Care 
Deficit Model links propositions regarding the "how and why" of utilizing essential oils 
as self-care in fibromyalgia. 
Orem's Self-Care Deficit Model 
Orem's (1985) propositions express facts or beliefs of nursing. Nursing is 
deliberate action; a function of practical nursing intelligence to bring about humane 
desirable conditions and environments. Nursing care is unique. It focuses on human 
beings by providing care in relation to environmental situations, living reality (context 
reality) and their functions. The platform for good nursing is nursing research and an 
appropriate evidence-based knowledge (Norton, 1995). There is great potential for col-
laborative research on EOs to explore clinical applications moving beyond low dose 
application paradigms (Buckle, 2007). 
Orem's (1985) holistic sense of self refers to one's whole being (p. 84). "The 
theory of self-care deficit assumes self-care" (p. 82). Performing SC is a decision, or 
choice. Prior to becoming a habit, reflection determines SC activities, or what is done, 
and how it should be done (p. 88). Therapeutic SC practice supports life processes, 
promotes normal functioning, and maintains normal growth, development, or maturation. 
Age, developmental stage, beliefs, habits, and cultures influence SC practices. Health 
states, environmental conditions, the effects of medical care, and other variables can 
modify SC (p. 19). Choices in SC behaviors can prevent, control, or cure disease pro-
cesses and injuries. For the purpose of this study, SC is the personal, practical, purpose-
ful, self-initiated action which demonstrates a pattern and sequence that benefits an 
individual's life, health, and well-being. 
Orem (1985) acknowledges that health deviations, illness and chronic disease can 
result in feelings of dysfunction or the inability to function normally. Medical care can 
increase a persons' SC requisites often accentuating components of pain, discomfort, 
frustration, and hazards. Integrated human functioning, behaviors, and habits change 
over time and redirect an individual's self-attention. The person who seeks and partici-
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pates in medical care to manage their health deviations is performing SC actions. 
Therapeutic SC demands vary to accommodate SC requisites and always include 
preventative health (p. 102). Daily executed SC measures become the context of life. 
Self-Care 
Self-care is a learned human behavior engaged in over time; characterized by deli-
berate action in the individual's environmental settings and within the context of their 
patterns of daily living (Orem, 1985, p. 106). The basis for SC judgment and decision-
making emerges from knowledge, purpose, common-sense and the meaning of SC. 
Social support and environments may also influence self-management (SM) (Gallant, 
2003). 
Self-Care Management 
Self-care management (SCM) can prevent or compensate for disability and 
promote well-being. Chronic illness management often requires the sufferer to assume 
extensive daily care responsibilities for day-to-day decisions and actions (Newman, et al., 
2004). A central concept in SM is self-efficacy or the "confidence to carry out a behavior 
necessary to reach a desired goal" (Bodenheimer, et al., 2002, p. 2469). For the purpose 
of this study, SCM is self-initiated; efficacious action integrated with consistency over 
time which demonstrates a pattern and sequence that benefits a person's life, health, and 
well-being. For the purpose of this study, interventions specifically focusing on aspects 
of patients' chronic illness management are often referred to as self-management 
interventions (SMI) (Newman, et al). 
Self Care Agency 
Orem (1985) defines an agent as the person taking action. Self-care agency is a 
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"complex acquired ability to meet one's continuing requirements for care that regulates 
life processes, maintains or promotes integrity of human structure, functioning and 
human development, and promotes well-being" (p. 105). Practicing SC agency requires 
motivation and skill to examine one's SC habits, appraise their benefits, recognize needs 
for change, and become knowledgeable about new SC requisites and interventions. 
Orem (1985) identifies extreme agitation, inexperience, and level of cognitive 
development as internal factors creating inference to SC appraisal and judgment. Exter-
nal factors, like a lack of resources or extreme social pressure, can also interfere with SC 
judgment. Existing conditions and possible options create thought and constitute rational 
judgment. Unreasonable judgment occurs when decisions are not in accord with existing 
therapeutic SC demands, existing health and well-being conditions. Individuals investi-
gate health care options and conditions making difficult decisions about what can and 
should be done. Decisions to follow SC actions determine whether or not SC requisites 
and outcomes are met. 
Orem (1985) views SC actions as subsystems within a total SC system or SM 
program regulating internal and external factors. Orem identifies 4 types of externally 
oriented SC actions: knowledge-seeking sequences (p. 10), assistance-and resource-
seeking behaviors, expresssive interpersonal action and externally oriented SC action 
sequences. 
Orem (1985) identifies 2 internally oriented SC actions. Resource-using action 
sequences control internal factors. Secondly, action sequences control the person's 
thoughts, feelings, and orientation to regulate internal factors or external orientations. 
Stages in Self-Care Decision-Making 
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There are 2 stages in SC decision-making (Orem. 1985). Stage one, or the 
"investigative and decision-making phase of self-care" (p. 123) focuses on the preceding 
operations leading up to a decision and the purpose of that decision. Effective SC re-
quires self-knowledge and information about environmental conditions. Adults usually 
follow normal decision-making patterns to meet daily living routines. Self-care requisites 
and decision-making patterns change during the illness trajectory. Medical or nursing 
professionals become useful resources to help arrive at a valid judgment. The first phase 
of SC concludes when a person reaches a decision. 
The person's choice at the closure of phase one sets the goals for stage two or the 
"production phase of self-care" (Orem, 1985, p. 123). The second phase concentrates on 
operations occurring after the SC decision that allows engagement in a selected course of 
action. Orem's action phase begins with the decision to meet specific, or a set of SC 
demands. The plan must specify what kind of action is to occur. 
Self-care "requires expenditure of effort to satisfy" known care demands (Orem, 
1985, p. 121). Sustainable effort is deliberate to achieve specific results or until there is 
evidence that the effort is not productive. The attention is on performed actions, and 
evidence to judge these actions to determine if the desired results are or have been 
achieved. 
Self-Care Deficits 
Self-care deficits (SCD) refer to the relationship between SC agency and thera-
peutic SC demands (Orem, 1985). "Self-care deficits are associated not only with indivi-
duals' limitations for performing care measure, but also with the lack of validity or effec-
tiveness of the SC in which they engage" (p. 130). A person's capabilities have limita-
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tions. Orem describes SCD, or limitations, as complete or partial. Partial SCD can be 
limited, extensive, or based on limitations to achieve one or several SC requisites. Com-
plete SCD means the individual has no capability of meeting a therapeutic SC demand. 
Deficits result in judgment and decision-making limitations. Disordered or im-
paired functioning results in new health-deviations and universal SC requisites. Newly 
prescribed, complex, SC measures create new needs. Performance integrates specialized 
knowledge and skill acquired through training and experience. 
Health-Deviation Self-Care Requisites 
Orem (1985, p. 99) describes 6 categories of health-deviation SC requisites. The 
first requires that an individual seek and secure appropriate medical assistance. The se-
cond involves awareness of and attendance to pathological conditions, their effects and 
results. In the third category, a person carries out medically prescribed diagnostic, thera-
peutic, and rehabilitative measures to prevent, regulate and integrate functioning. The 
next category requires an awareness or regulation of discomforting or deleterious effects 
on development. The fifth category modifies SC and self-image to accept oneself in a 
particular state of health with specific forms of health care needs. Finally, an individual 
learns to live with the effects of the pathological condition. Self-care expression is a 
human regulatory function. 
Calculating Therapeutic Self-Care Demand 
Orem (1985) reviews 6 operations to determine therapeutic SC demands (p. 100). 
The first involves identification and particularization of existing, emerging, or projected 
developmental and health-deviation SC requisites. The second operation involves identi-
fication of internal or external variables that affect the attainment of SC. The third shows 
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interrelationships among various SC requisites. The next operation determines how SC 
requisite interventions affect other SC requisites. The fifth operation is an interventional 
course of action to meet SC requisites. A designed formulation for total SC action with 
specified duration and integration of elements occurs within the context of daily living. 
Summary of Orem's Theoretical Model 
Orem's (1985) SCD is the organizing theory for this CSR. Nursing agency is seen 
as the interface to SC agency. Individuals make SC decisions based on their knowledge, 
culture, values, age, and maturity and within the context of their lived experience. 
Nursing encompasses both art and science. A nurse synthesizes knowledge to create 
problem solutions within the individual's environment. Nurses provide care for others 
who are partially or completely unable to meet their SC requisites. The nurse's unique 
education, knowledge base, and experience in practice create the platform to help others 
live through the lived contextual experience of chronic illness. 
Self-Care 
The "hidden" health care system for chronicity is now SC (Keysor, et al., 2003, p. 
724). Patients are in control of important SM decisions and can veto health professional 
recommendations (Glasgow & Anderson, 1999). Courage to live each day with chronic 
conditions is a challenge with ramifications. Self-care management narrates this chal-
lenge within the context of human suffering. Self-management and SC are interchange-
able terms. People self-initiate SC activities with intent to promote health and/or manage 
chronic conditions (DeFriese, et al., 1994; Hang, et al., 1991; Keysor, et al.; Ory, et al., 
1998; Holman & Lorig, 2000). 
Self-management implies more than simple adherence to treatment guidelines 
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(Hummel, 2009; Newman, et. al, 2004). The scope of SM encompasses an individual's 
ability to manage symptoms, or to treat chronic conditions associated with physical and 
psychosocial consequences and lifestyle changes (Barlow, et al., 2002). 
Interventions 
The enduring nature of chronic conditions mandate SMI as imperative, inevitable, 
and nonoptional behaviors (Bodenheimer, et al, 2002; Cross, 2007). A person uses SMI 
to create processes and opportunities to increase treatment involvement and bring control/ 
order into their lives (Kralick, et al., 2004; Newman, et al., 2004). Care strategies reflect 
protracted time frames; clarify patient roles and acceptance of responsibilities (Newman, 
et al.; WHO, 2002). 
Larsen and Hummel (2009) discuss that a disease focus cannot manage the illness 
experience for the person. Chronic illness mandates heterogenic adaptation within the 
reality context of each unique individual. Therefore, individuals with chronic conditions 
use a variety of techniques to manage symptoms and maintain social role normalcy 
(Larsen, 2009). Self-control opportunities or SM emerge as outcomes of uniquely per-
ceived and processed stressors within the lived context (Delmar, et al., 2006). More than 
400 published articles provide evidence that interventions promoting patient roles in the 
management of chronic conditions result in improved outcomes (WHO, 2002). A per-
son's participation in decision-making and treatment planning increases efficacy and effi-
ciency (Holman & Lorig, 2000). Individuals can choose actions which improve their 
health. They need knowledge, motivation and skills to cope with the lived experience of 
chronic conditions (WHO). The efficacy of SCM encompasses self-monitoring, effective 
cognitive, behavioral and emotional responses to maintain QOL (Barlow, et al., 2002). 
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"Prevention and health promotion should be part of every health care encounter, 
but this is far from routine clinical care" (WHO, 2002, p. 34). Health care workers gain 
monetary rewards proportionately to the volume and cost of delivered services but not for 
engaging in innovative, health promoting clinical practice (WHO). Interventions favor 
medical technology and pharmacological agents at the expense of low-tech strategies, but 
daily SC health choices are more influential than medical interventions alone (WHO). 
This paradigm shifts from industrial age health care provisions (Cross, 2007) to a 
challenge for prepared, proactive practice teams interacting with informed, activated 
patients (Bodenheimer, et al, 2002). 
Embedded Analysis Concepts 
The following indepth literature reviewed additional data for embedded concept 
analysis within the CSR. Previously discussed within Orem's (1985) theoretical 
framework, SC integrated into the rubric of FM and aromatherapy (AT). Fibromyalgia 
symptoms and treatment discussed a multimodal, IM approach. Aromatherapy included 
a detailed discussion of EOs emphasizing those used by the informant in her self-care 
regimen. 
Fibromyalgia 
The American College of Rheumatology defines FM as a syndrome of diffuse 
muscle pain for a minimum of 3 months duration with pain on palpation of at least 11 of 
18 tender points (Wolfe, et al, 1990; Crowther-Radulewicz, 2010; Crowther-Radulewicz, 
& McCance, 2010). Points occur bilaterally on the body. Crowther-Radulewicz 
classifies FM as a chronic pain, subjective complaint syndrome rather than presenting 
with unique pathophysiologic characteristics. Due to this vagueness, FM is a diagnosis 
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of exclusion without confirmatory common laboratory diagnostic tests; patient history is 
important for diagnosis (D'Arcy, 2008). 
Anteriorly, generalized muscle tenderness points are found at 4 bilateral locations 
(Freundlich & Leventhal, 1997). The first are located in the low cervical neck areas. 
These are palpated in the anterior aspects of the fifth through seventh cervical 
intertransverse spaces. At the second rib, the second costochondral junctions are 
palpated. The third palpation points are located 2 centimeters (cm) distal to the lateral 
epicondyles. The fourth palpation points are located at the knees in the medial fat pad 
proximal to the joint line. 
Posteriorly, 5 bilateral points are examined for tenderness (Freundlich & 
Leventhal, 1997). The first point of tenderness is located at the occiput with palpation at 
the suboccipital muscle insertion sites. The second point is found at the trapezius mid-
point of the upper border; the third palpation point at the supraspinatus above the medial 
border of the scapular spine. The fourth palpation point is examined in the upper outer 
quadrants of the gluteal or buttock muscles. Finally, the fifth palpation point is located at 
the greater trochanter, specifically, posterior to the trochanteric prominence. 
Etiology 
Etiology is debatable and unknown with common, multiple precipitating factors 
including viral illness (Epstein-Barr, hepatitis C, parovirus, chronic fatigue syndrome, 
human immunodeficiency virus infection, lyme disease, physical or emotional trauma, 
catastrophic events, psychologic or emotional distress, and medications, especially 
steroid withdrawal (Crowther-Radulewicz, 2010; Sierpina & Carter, 2002). Aggregating 
data suggests that disordered central pain processing contributes to its pathogenesis 
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(Abeles, Pillinger, Solitar, & Abeles, 2007). Rheumatic diseases may coexist or initially 
manifest with FM. 
It seems that genetic and environmental factors play roles in FM susceptibility 
(Arnold, Hudson, Hess, Ware, Fritz, Auchenbach, et al., 2004; Buskila & Neumann, 
1997; Buskila & Sarzi-Puttini, 2006). Although the pathogenesis of FM is not well 
understood, family studies show familial aggregation of FM and related conditions are 
most probably polygenic in nature (Buskila & Sarzi-Puttini; Staud, 2006). 
Lee, Choi, Ji, Song (2010) completed a meta-analysis of 18 studies of candidate 
gene polymorphisms contributing to FM susceptibility using allele contrast, recessive, 
dominant models and a contrast of homozygotes. Twenty-one different comparisons 
were considered. Seventeen candidate genes and over 35 various polymorphisms in FM 
studies were identified. The overall odds ratio (OR) association between the C allele and 
FM was 1.222 (95% CI = 1.053-1.688,/? = 0.017). Authors' concluded that the serotonin 
5-HT2A receptor 102T/C polymorphism confers susceptibility to FM (p. 218). 
Sierpina and Carter (2002) propose additional theories to explain the etiology of 
FM. Although primary etiology is undetermined, neuroendocrine axis imbalance is pro-
bably a key variable. Examples of this imbalance includes automatic nervous system 
abnormalities, altered norepinephrine, low insulin-like growth factor-1 levels, decreased 
serotonin and tryptophan levels and altered levels of substance P, a peptide neurotrans-
mitter, and norepinephrine. Other presentations in FM include lower cerebral blood flow, 
low sympathetic tone, orthostatic intolerance, visceral dysfunction and vasomotor insta-
bility. The second central variable is sleep disruption (disturbed non-rapid eye move-
ment [REM]). Both variables seem central. Another theoretical hypothesis suggests 
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hypothalamic-pituitary-adrenal (HPA) axis dysfunction. Many researchers report abnor-
mal concentrations of central nervous system (CNS) neuropeptides, biogenic amines, and 
alterations of the HP A axis (Bradley, Alarcon, Sotolongo, Weigent, Alberts, Blalock, et 
al., 1998; Neeck, 2000; Russell, Orr, Liftman, Vipraio, Alboukrek, Michalek, et al., 1994; 
Vaeroy, Helle, Forre, Kass, & Terenius, 1998). 
Fibromyalgia Symptoms 
Fibromyalgia is a syndrome comprised of many complex symptoms. The 
following literature reviews highlights on some of the most important chronic symptoms. 
Pain 
The chronic pain syndrome of FM represents the extreme end of musculoskeletal 
(M/S) pain affecting women 9:1 times more often than men (Staud, 2006). Sierpina and 
Carter (2002) report that over 90% of FM patients report fatigue, generalized pain, 
morning fatigue, and stiffness. Pain perception, known as nociception, normally occurs 
peripherally where stimuli are originally felt, spinal cord where stimuli processing 
occurs, and the brain where stimuli interpretation equates to pain (Sierpina & Carter). 
Pain is a burning or gnawing sensation; an altered pain process that lowers mechanical 
and thermal pain thresholds; produces high pain ratings as a result of provoking stimuli; 
alters temporal summation of pain stimuli as the outcome (Crowther-Radulewicz, 2010; 
Bennett, 2007; Dannecker, Knoll, & Robinson, 2008). 
Allodynia or the mechanical pain hypersensitivity experienced in FM patients 
seems to be widespread (Kosek, Ekholm, & Hansson, 1995). Muscle abnormalities, in-
cluding trigger points, are thought to act as pain generators in FM contributing to pain 
through mechanisms of pain amplification (Staud, 2006). Biomechanical mediators can 
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sensitize muscle nociceptors thereby indirectly inducing or contributing to central sensi-
tization (Staud). The cerebrospinal fluid (CSF) of FM sufferers shows 3-5 times the 
normal substance P levels, a pain-facilitating agent (D' Arcy, 2008). Nerve growth factor 
is also elevated with FM which can affect sensory processing (Wolfe, et al., 1990). Ex-
posure to cold aggravates FM pain (Berglund, Harju, Kosek, & Lindblom, 2002; Carli, 
Suman, Biasi, & Marcolongo, 2002). 
Others 
Crowther-Radulewicz (2010) reports other characteristic symptoms of FM as in-
creased sensitivity to touch, absence of localized or systemic inflammation, fatigue, and 
sleep disturbances. Anxiety related to the diagnosis of FM is almost universal. Other 
symptoms include migraine HA in 45%, irritable bowel symptoms (IBS) in 41.8%, dys-
menorrhea, female urethra syndrome, endometriosis, noncardiac chest pain, plantar heel 
pain, temporomandibular joint (TMJ) pain, sinusitis, Sjorgren's syndrome, pares-thesia, 
excessive sensitivity to cold (Raynaud-like) in 50% of the individuals; 25% seek psycho-
logical support for depression (Bonafede, Downey, & Bennett, 1995; Cleveland, Fisher, 
Brestel, Esinhart, & Metzger, 1992; Crowther-Radulewicz; Harvey, 1993; Lapossy, 
Gasser, Hrycaj, Dubler, Samborski, & Muller, 1994; Mukerji, Mukerji, Alpert, & 
Selukar, 1995; Nicolodi & Sicuteri, 1996; Paira, 1994; Plesh, Wolfe, & Lane, 1996; 
Sinaii, Cleary, Ballweg, Nieman, & Stratton, 2002; Sivri, Cindas, Dincer, Sivri, 1996; 
Yunus, Masi, & Aldag, 1989a). Neurotransmitter deficits from serotonin, norepineph-
rine, and dopamine might account for some of the depressive symptoms associated with 
FM (D'Arcy, 2008). 
Fibromyalgia Treatment 
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There is no cure for FM and treatment is usually multimodal (Sierpina & Carter, 
2002). The main goal of treatment is symptom management frequently involving pharm-
acological and nonpharmacological interventions (Sierpina & Carter). Rooks (2007) dis-
cusses current treatments for FM including medical (pharmacology, physical, and psych-
ological therapies) SM and CAM interventions. Randomized control trial CAM FM 
studies are increasing from the past decade, yet treatment remains inadequate (Holdcraft, 
et al., 2003). Individuals continue to suffer from persistent symptoms which result in 
functional limitations and declining QOL. Evidence-based standards of care are not 
available. 
Pharmaceuticals 
Tried pharmacological agents for FM are extensive (Ko, et al., 2005). In 2005, 
best supported medications were low-dose tricyclic antidepressants, but benefits were 
short-term without significance when compared to placebo at 6 months of study (Caruso, 
Puttini, Cazzola, & Azzolini, 1990; Clauw & Crofford, 2003; Tofferi, Jackson, & 
O'Malley, 2004). Many published trial medications were ineffective in FM pain manage-
ment including acetaminophen (paracetamol), 4% lidocaine sphenopalatine nerve blocks, 
lidocaine intravenously (IV) at 5 milligram (mg)/kilogram (kg), morphine sulfate IV 0.3 
mg/kg, ibuprofen, naproxen, prednisone 15 mg daily, citalopram, and Zolpidem (Clark, 
Tindall, & Bennett, 1985; Goldenberg, Felson, & Dinerman, 1986; Gunther, Mur, 
Kinigadner, Miller, 1994; Janzen & Scudds, 1997; Moldofsky, Lue, Mously, Roth-
Schechter, & Reynolds, 1996; Norregaard, Volkmann, & Danneskiold-Samsoe, 1995; 
Sorensen, Bengtsson, Ahlner, Henriksson, Ekselius, & Bengtsson, 1997; Yunus, Masi, & 
Aldag, 1989b). Medication treatments were also used to improve sleep, decrease 
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inflammation, supplement vitamin D deficiency, and certain CNS-active medications, 
like pregabalin (Lyrica®) (Crowther-Radulewicz, 2010; Mease, Russell, Arnold, Florian, 
Young, Martin, et al., 2008). 
To date, the only US FDA approved medications for FM are pregabalin (Lyrica®) 
and duloxetine (Cymbalta®). Pregabalin treats pain and has a short onset of action, less 
than one week (Klipa & Russeau, 2009). Duloxetine is a serotonin and norepinephrine 
reuptake inhibitor that treats major depressive disorders (Arnold, Lu, Crofford, 
Wohlreich, Detke, Iyengar, et al, 2004; Nemeroff, Schatzberg, Goldstein, Detke, 
Mallinckrodt, & Lu, 2002). 
Physical Therapies 
Multiple modes of physical therapies were helpful for FM pain. Aerobic exercise 
(Burckhardt, Mannerkorpi, Hedenberg, Bjelle, 1994; McCain, Bell, Mai, Halliday, 1988; 
Richards & Scott, 2002; Wigers, Stiles, Vogl, 1996) especially when combined with flex-
ibility and strength training were found superior to relaxation alone (Martin, Nutting, 
Macintosh, Edworthy, Butterwick, & Cook, 1996). Pool exercise, hydrotherapy and 
strengthening exercises were also efficacious (Ammer & Melnizky, 1999; Cedraschi, 
Desmeules, Rapiti, Baumgartner, Cohen, Finckh, et al. 2004; Gunther, et al., 1994; 
Hakkinen, Hakkinen, Hannonen, Alen, 2001; Karagulle & Karagulle, 2004; 
Mannerkorpi, Nyberg, Ahlmen, & Ekdahl, 2000; Rooks, Silverman, & Kantrowitz, 
2002). Low intensity training programs were recommended to support compliance and 




Psychological stress is palpable for individuals suffering with FM. Mind body 
therapies such as cognitive-behavioral therapy (CBT), biofeedback, hypnotherapy, 
meditation-based stress reduction, imagery, and self-efficacy show degrees of efficacy 
(Haanen, Hoenderdos, van Romunde, Hop, Malle, Terwiel, et al., 1991; Kaplan, 
Goldenberg, Galvin-Nadeau, 1993; Redondo, Justo, Moraleda, Velayos, Puche, Zubero, 
et al., 2004; Sierpina & Carter, 2002; Williams, Cary, Groner, Chaplin, Glazer, 
Rodriguez, et al., 2002) as well as group therapy and relaxation (Bennett, Burckhardt, 
Clark, O'Reilly, Wiens, & Campbell, 1996; Keel, Bodoky, Gerhard, & Muller, 1998; 
Sierpina, & Carter). 
Essential Oils 
Essential oils have been studied for the treatment of FM. These nonallopathic 
treatments are discussed below in depth under the topic of EOs used for chronic 
conditions. 
Aromatherapy 
Aromatherapy is one of the fastest growing CAM therapies (Lis-Balchin, 2006) 
using EOs, or the essence of plants, herbs, and trees for therapeutic purposes as one 
possible option to pharmacotherapy (Ballard, O'Brien, Reichelt, & Perry, 2002; Kravits 
& Berenson, 2010). For the purpose of this study, AT is a CAM intervention that uses 
volatile, essential plant oils for an individual's biopsychosocial well-being. Essential oils 
are centuries old. The Holy Bible mentions their use before Christ's birth. Three 
categories define AT: aromachology, AT and aromatology. 
Aromachology 
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Aromachology is defined by the Sense of Smell Institute (SSI) as "a concept 
based on systematic, scientific data collected under controlled conditions" (Lis-Balchin, 
2006, p. 3). It studies interrelationships of psychology and fragrance technology to 
transmit through odor a variety of feelings directly to the brain (Lis-Balchin). 
Aromatherapy 
Aromatherapy is defined by SSI as "the therapeutic effects of aromas on physical 
conditions ... as well as psychological conditions" (Lis-Balchin, 2006, p. 3). It is an 
offshoot of herbal medicine influencing the limbic system which encodes odors into 
associations and memories that, "...when awakened alter basic physical functions such as 
heart rate, blood pressure, breathing, and hormone level" (Matzo & Sherman, 2006, p. 
59). Pleasant scents can become memories of joy, safety, love and caring. 
Aromatology 
Aromatology uses EOs as internal medicines (Franchomme & Penoel, 1990); 
includes the intensive application of neat (undiluted) oils through the skin (3-45 mL/day) 
(Lis-Balchin, 2006). Aromatology concentrates on the effects of chemicals in the EOs 
taken internally via oral, anal, vaginal or other possible openings by medically qualified 
doctors or herbalists. 
Physiology and Application 
The physiology involved in the response to EOs is complex and undergoing 
continual investigation. This section reviews physiological interactions. 
There are many methods of administration for EOs. The most commonly known 
is inhalation through the use of diffusion. Body powders, candles, baths crystals and 
compresses are also methods of administration (Lis-Balchin, 2006; Schiller & Schiller, 
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2001). Self-application refers to an application of the EO on the skin, rubbing it in until 
it is fully absorbed (Schiller & Schiller). For the purpose of this study, transdermal 
application refers to SC application of any EO on the skin with rubbing into the skin until 
it is fully absorbed on any body location. 
Olfactory and Inhalation 
Smell is closely linked to emotions and vastly more sensitive than taste (Lis-
Balchin, 2006). Humans are capable of registering at least 10,000 different fragrances. 
"The sense of smell stimulates reactions and actions at both subconscious and conscious 
levels" (Rubert, Long, & Hutchinson, 2007, p. 31). 
Odors almost immediately reflect on the brain through the olfactory system 
(Buckle, 2001; Lis-Balchin, 2006). The olfactory membrane exposes the CNS brain cells 
directly to the environment (Fischer-Rizzi, 1990). Molecules stimulate impulse passage 
along the olfactory tract to the primitive limbic system, amygdala, or noncognitive, 
middle brain entering the bloodstream via the lungs (Holmes & Ballard, 2004; Lis-
Balchin; Mariano, 2006). 
"Odor stimuli in the limbic system or olfactory brain release neurotransmitters -
among them encephalin, endorphins, serotonin, and noradrenalin" (Fischer-Rizzi, 1990, 
p. 27). Encephalin and endorphins reduce pain and create a feeling of well-being. 
Encephalin also produces pleasant, euphoric sensations while endorphins stimulate sexual 
feeling. Serotonin helps relax and calm; noradrenalin acts as a stimulant (Fischer-Rizzi). 
Factors to consider in treatment response outcomes of inhaled EOs are 
categorized into psychological aspects and neurochemical effects by Holmes and Ballard 
(2004). Psychological variables in treatment response are the individual's perception of 
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the pleasantness of an odor and the individual's past association with an odor. 
Neurochemical effects are identified as the inhibition of glutamate binding, gamma-
aminoburyric acid (GABA) augmentation, and acetylcholine receptor binding. 
Transdermal Application 
Essential oils are lipid soluble and rapidly absorbed into the bloodstream when 
applied externally, inhaled or ingested (Buckle, 2001; Maddocks-Jennings & Wilkinson, 
2004). "Any essential oil placed anywhere on the body is transdermal and can reach 
every part of your body within minutes" (Stewart, 2003, p. 16). Transportation through 
the human body occurs via the circulatory, connective and lymphatic systems, crossing 
through tissues, cell walls, membranes and blood brain barriers (Holmes & Ballard, 2004; 
Fischer-Rizzi, 1990; Stewart, 2003, 2005). Elimination of EO is through lung exhalation 
(carbon dioxide), kidney (urinary) excretion, nose, mouth and feces (Fischer-Rizzi; Lis-
Balchin, 2006; Maddocks-Jennings & Wilkinson). 
Aromatherapy Massage 
Aromatherapy massage (ATM) combines the use of EOs with massage therapy. 
This route has more research studies to report than other methods (Tables 1). Difficulty 
arises, however, in determining whether it is the massage component or the EOs that 
comprises research results. 
Popular and widely practiced within cancer settings, ATM reduces stress and im-
proves mood in terminally ill patients combined with touch and listening skills (Lis-
Balchin, 2006; Rravitz & Berenson, 2010; Wilkinson, Love, Westcombe, Gambles, 
Burgess, Cargill, et al., 2007). Roman chamomile, lavender, and clary sage are often 
used for ATM with beneficial effects on physical and psychological symptoms (Rakel, 
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2007; Wilkinson, Aldridge, Salmon, Cain, & Wilson, 1999). 
Kite, Maher, Anderson, Young, Wood, et al. (1998) found that ATM helped 
reduce psychological distress and improved symptom management in cancer patients.. 
After a course of 6 ATM sessions, there was a significant improvement in the Hospital 
Anxiety Depression Scale (HADS) in 58 cancer patients at p < .001. Large RCTs 
indicated that ATM reduced levels of anxiety in cancer patients for short term effects 
(Fellowes, Barnes, & Wilkinson, 2004; Wilkinson, et al., 1999; Wilkinson, et al., 2007). 
Hadfield (2001) studied 8 patients with primary brain tumors attending their first 
radiotherapy appointment to determine whether ATM would reduce anxiety. Physical 
parameters, HADS, and semi-structured interviews were used for measurements. There 
was no significant improvement in the HADS scores within this small sample size, but 
significant improvement was shown in 4 physical parameters. Patient interviews verified 
relaxation after the ATM supporting QOL improvement. 
Wilkinson, et al. (2007) identified the only outcome predictor for anxiety and de-
pression as AT versus ATM. Komori, Fujiwara, Tanida, and Namura (1995) reported 
that adjunctive AT allowed for decreased antidepressant doses within a small, random-
ized trial. Fellowes, et al. (2004) showed psychological well-being from massage with 
(w) or without (wo) AT to decrease anxiety. Cooke and Ernst (2000) completed a 
systematic review of AT literature concluding that ATM studies suggested a mild, tran-
sient anxiolytic effect. Richards, Gibson, and Overton-McCoy (2000) reviewed 22 
articles examining the effect of massage therapy on relaxation and reported the most 
consistent finding as a reduction in anxiety. Thus, design flaws and small samples sizes 
concluded the need for improved methodologies on larger scales over longer periods of 
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time to confirm findings. 
Physiological & Symptom Management 
Research shows that in vivo physiological parameters and symptom management 
change through inhalation or transdermal applications of EOs (Table 2). Findings sug-
gest that stimulating EOs affect the sympathetic nervous system (SNS). Calming EOs 
relax it. 
Essential Oils 
Essential oils (EOs) are used in AT and considered mankind's first medicines for 
physical and spiritual health (Lewis, et al., 2003; Smith, 2003). These aromatic volatile 
liquids are composed of a plant's immunity distilled as extracts from shrubs, flowers, 
stems, bark, branches, roots, bushes, leaves, needles, fruits, and seeds; produced in 
practically every country of the world {Essential Oils Pocket Reference fEOPRJ), 2004; 
Halm, 2008; Helms, 2006; Lewis, et al.; Stewart, 2005; Worwood, 1996). 
Most EOs promote healing. Usually non-toxic, and harmless to human tissue, 
EOs demonstrate a long history of safe traditional use when properly administered 
(Dunning, 2005; Fischer-Rizzi, 1990; Rose, 2006; Stewart, 2003, 2005). Stewart (2003) 
identifies 6 ways that EOs support people as antimicrobials, antioxidants, balancers of 
bodily functions and emotions, raising bodily frequencies, and increasing our spiritual 
awareness (p. 34). Growing evidence supports EO use in nursing care (Dunning). Little 
focus is given, however, to the real clinical potential of EOs (Buckle, 2007). Research 
supporting EOs1 efficacy claims for clinical implementation is unavailable or highly 
flawed, yet combined with observations, warrants further study (Lewis, et al., 2003; 
Spencer & Jacobs, 1999). 
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Definition of Essential Oils 
Holistic therapies used in CAM require the purest EOs which, when properly 
stored and sealed, have centuries of shelf lives (Stewart, 2005). For the purposes of this 
study, EOs are volatile liquid extracts from shrubs, flowers, stems, branches, bark, roots, 
bushes, leaves, needles, fruits, and seeds; produced around the world {EOPR, 2004; 
Halm, 2008; Helms, 2006; Lewis, et al., 2003; Smith, 2003; Stewart, 2005; Worwood, 
1996). 
The EOPR (2004) describes 3 therapeutic models for treatment. The English 
model advocates body massage for relaxation and stress reduction using small amounts of 
EOs in a carrier or diluent oil for application. The French focus on internal ingestion and 
neat or undiluted topical application of therapeutic grade EOs. The Germans use EOs for 
inhalation. For the purpose of this CSR, neat and diluted EO will be utilized by the 
informant without internal ingestion. 
Possible adverse side effects while using EOs include photosensitivity, allergic 
reactions, dermatitis, nausea and headache (HA) (Kravitz & Berenson, 2010). Essential 
oils might enhance or reduce the effects of medications (Perez, 2003). 
Essential Oil Standards 
The quality and quantity of EOs are mediated by: location and geographical 
region of growth, altitude, moisture, climate, soil condition/fertilizer (organic or 
chemical), part(s) of the plant producing the oil, season, time of plant material harvest, 
method of harvesting, and distillation processes {EOPR, 2004; Schiller & Schiller, 2001). 




Preservation of delicate aromatic chemical compounds within the EO is impera-
tive to attain a therapeutic grade {EOPR, 2004). Laboratories can not replicate EO mole-
cules or isomers. Plants from the proper botanical genus, species, and cultivar grown wo 
chemical soil fertilizers, herbicides, and pesticides are desirable (Stewart, 2005). 
"Inferior quality or adulterated oils most likely will not produce therapeutic results and 
could possibly be toxic" {EOPR, p. 10). Extraction is usually by steam distillation at 
minimum temperatures and pressures wo using chemical solvents in the extraction pro-
cess. Distillation, condensation, and separation are performed in receptacles constructed 
with relatively inert materials. For the purpose of this study, a therapeutic grade EO is 
natural, wo chemical additives, distilled from parts of plants (botanical herbs) and bottled 
in brown, amber, or blue glass containers with air tight, non-reactive lids that shield from 
light (Stewart, 2005). 
Standards for Therapeutic Grades 
Standards for therapeutic grade EOs are not set by any government agency, or 
FDA. Principal constituents that quality EOs should have are outlined in a set of 
European standards known as the Association French Normalization Organization 
Regulation (AFNOR) and International Standards Organization (ISO) from Switzerland 
{EOPR, 2004; Stewart, 2005). The AFNOR is a team written standard lead by 
government-certified botanical chemist Herve Casabianca working with several analyti-
cal laboratories throughout France. Primary constituents in an EO must occur in certain 
percentages to be considered therapeutic. The ISO sets standards for therapeutic grade 
EOs adopted from AFNOR. If EO constituents are too high or low, it cannot be certified. 
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Marriott, Shellie, and Cornwell (2001) discuss the use of gas chromatography 
(GC) to analyze volatile and semi-volatile substances. This technique is available to 
contrast and compare EOs by determining composition, quality, and adulteration. This 
technique can discover new compounds or chemical classes. This powerful separation 
method reassures the CAM practitioner that EOs are medicinal grade for the use of 
therapeutic treatments. This process can also raise the cost of EOs. 
Chemistry of Essential Oils 
One drop (gtt) of EO contains about 40 million-trillion molecules creating 
complex chemical compounds composed of isoprene units (carbon and hydrogen atoms). 
Major components are phenols and phenylpropanoids (P), monoterpenes (M) and 
sesquiterpenes (S) (Stewart 2003). 
Unfriendly living conditions are created with P so that viruses and bacteria cannot 
live. The function of P is to clean cell receptor sites facilitating healthy cellular 
communication. Examples of EOs with P compositions include: clove, cassia, basil, 
cinnamon, oregano, anise, and peppermint which was used as an ancient medication over 
10,000 years ago (Sego, 2008; Stewart, 2003). 
Essential oils also contain M consisting of 2 isoprene units that can reprogram 
miswritten information in cellular memory or deoxyribonucleic acid (DNA). Examples 
of EOs with M include galbanum, angelica, hyssop, rose of sharon, peppermint, juniper, 
frankincense, spruce, pine, cypress and myrtle (Stewart, 2003). 
Another main constituent of EOs is S consisting of 3 isoprene unit compounds 
found in cedarwood, vetiver, spikenard, sandalwood, black pepper, patchouli, myrrh, and 
ginger; at lower percentages in galbanum, onycha, and frankincense (Stewart, 2003). 
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These molecules deliver oxygen to the cells. They "can erase or deprogram miswritten 
codes in cellular memory"; thought to be especially effective in fighting cancer by 
deleting garbled information creating "an environment where cancer cells can't 
reproduce" (Stewart, 2003, p. 29). 
Oils containing P, M, and S are useful in addressing many illnesses, injuries, and 
disease conditions. Stewart (2003) hypothesizes that P, M, S oils cleanse receptor sites, 
deprogram bad information, and reprogram correct information (p. 30). 
Perez (2003) uses the chemical structures of EOs to categorize mechanisms of 
action. Terpenes have antiviral, antiseptic, bactericidal and anti-inflammatory properties. 
Esters are fungicidal and have a sedative effect. Aldehydes are both antiseptic and 
sedative. Ketones reportedly ease congestion and may be very toxic. Alcohols have 
antiseptic and antiviral attributes and are generally regarded as nontoxic in nature. 
Phenols can be stimulating to the sense and oxides can be used as expectorants (p. 595-
596). Ginger's antimicrobial effects are contributed to M: 1, 8-cineole, P-pinene, and a-
terpineol (Martins, Salgueiro, Goncalves, da Cunha, Vila, Canigueral, et al., 2001). 
Chronic Conditions and Essential Oils 
"Most chronic and life-threatening diseases become whole-person experiences 
that inevitably include suffering" (Ferrell & Coyle, 2008, p. 9). Suffering is a private, 
lived experience of a whole person, individually unique resulting from the most 
important aspects of threatened or lost personal identity (Kahn & Steeves, 1996). 
Suffering is complex and perceivable through the lens of a contextual praxis (Georges, 
2002). A caring environment can influence a person's suffering positively or negatively 
(Kahn & Steeves). Within this environment, perceptions of fragrances in AT are highly 
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personalized and dependent on social customs and the individual's historical experiences 
(Matsui, Declercq, Sparacio, Voight, Marenus, Maes, 2002). 
Nursing as a practice discipline acknowledges that "competence resides in the use 
of context-specific knowledge, skills and clinical judgments to meet patient and families' 
health needs" (Murray, 2008, p. 45). The relief of suffering is at the core of nurses' work 
and nothing is routine (Ferrell & Coyle, 2008). The use of EOs in American healthcare is 
not routine, but since conventional medicine does not offer cures for chronic illnesses it 
seems urgent that other interventions be researched to mitigate suffering. One of these 
CAM interventions is AT or the use of EOs. 
Fibromyalgia 
Holdcraft, et al.'s (2003) evaluation post systematic review of empirical evidence 
concludes that acupuncture has the strongest supportive evidence for FM, magnesium, S-
adenosyl-L-methionine (SAMe), and massage therapy have moderate evidence. Authors 
state that Chlorella pyrenoidosa (a green alga dietary supplement), relaxation, 
biofeedback, magnet therapy, homeopathy, botanical oils, balneotherapy (sulphur baths) 
anthocyanidins (common plant pigments) and dietary modifications have limited 
empirical evidence (p. 681). Other treatments include education, exercise, and cognitive 
therapy (Crowther-Radulewicz, 2010). For the purpose of this study, literature reviews 
will focus on EOs and AT treatments. 
Ammer and Melnizky (1999) completed and investigator-blinded RCT assessing 
10 whirl-bath (3 times per week) treatments using pine oil {n = 7), valerian {n - 12) or 
plain water {n = 11). Results indicated that valerian baths improved sleep. Pine oil 
increased sensitivity to pain. Plain water whirl-baths appeared to decrease the intensity 
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of pain. Baths with EOs promoted well-being. This was a small sample size wo patient 
blinding and missing data in the final analysis. 
A randomized controlled trial (RCT) was conducted by Ko, et al. (2006) using a 
patented OTC topical (024) for a block of 4-6 weeks which consisted of a proprietary 
blend of 6 EOs including rosemary, peppermint, camphor, aloe vera, and lemon/orange. 
Subjects were recruited by newspaper advertisements and FM internet support groups. 
Clinical diagnoses were confirmed through medical evaluation. Treatment instructions 
were given by a blinded registered nurse (RN) consultant. Topical 024 was given to half 
of the FM participants (n = 65) applying every 4 hours PRN pain avoiding eyes, mucous 
membranes, genitalia, or open wounds. "Placebo oils (peppermint oil) identical in smell 
and appearance to active oils were supplied to the other half (n = 68) (p. 5). Authors 
reported the primary action as a counter-irritant for pain sensation by stimulating large A-
beta sensory fibers inhibiting pain from A-delta and C fibers at the dorsal horn. Local 
inhibition of pain transmitters included bradykinin, histamine, and prostaglandins. Based 
on a 7 point subjective Lanier scale,p < .0001 in the treatment group w a significant mild 
to moderate pain management improvement over the control group who noted no 
significant change. Statistical analysis was performed using Statistical Analysis 
Software, but specific tests were not mentioned within the article to determine validity of 
reported data. Actual frequency of participants' use of the control or 024 variable or 
amount of application was not reviewed in the article. The EO species, concentrations, 
and compounding processes were also excluded. Although larger and longer studies need 
to confirm findings, authors concluded that this pilot RCT suggests that topical 024 may 
be effective for FM pain (Ko, Hum, Traitses, & Berbrayer, 2007). 
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Lukaczer, Darland, Tripp, Liska, Lerman. Schiltz, et al (2005) investigated the 
efficacy of Meta050, a proprietary combination of reduced iso-alpha-acids from hops, 
rosemary extract and oleanolic acid, in an open-label, 8-week observational trial. 
Participants (N = 54) were suffering from osteoarthritis, rheumatoid arthritis and FM 
pain. They were given 440 mg TID for 4 weeks. During the last 4 weeks of the study, 
the dose was increased to 880 mg twice daily (BID) for the majority of patients. 
Outcomes were measured using a VAS for pain and associated specific condition 
symptoms. Arthritic subjects (40% - 50%) showed a statistically significant decrease in 
pain (p < 0.0001; Wilcoxon-ranked sums) and AIMS2 {P < 0.0001) wo serious side 
effects. Unfortunately, FM subjects did not significantly improve. 
Osborn, Barlas, Baxter, and Barlow (2001) conducted a survey of current practice 
among aromatherapists in the UK to determine the management of rheumatic disease 
symptoms using EOs. The overall response rate was 54% {n = 269) and 48% {n = 240) 
were currently practicing AT; 95% (n = 229) were females with a mean age of 42.9 years 
(SD = 9.51). The mean duration of AT practice was 4.2 years (SD = 3.1). The most 
frequently addressed symptom was stress (74% of n = 178 respondents). Lavender 
{Lavandula angustifolia) and rosemary {Rosmarinus officinalis) were the EOs used for 
painful joints. Stiffiiess was treated with Rosemary {Rosmarinus officinalis) and 
marjoram {Origamium marjorana). Joint inflammation was treated with German 
chamomile {Chamomilla recutita) and Roman chamomile {Anthernis nobilis). Pain was 
treated with lavender {Lavandula angustifolia) and Roman chamomile {Anthernis 
nobilis). Depression symptoms were treated with bergamot {Citrus bergamia) and {Rosa 
damascena). Anxiety symptoms were treated with lavender {Lavandula angustifolia) and 
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frankincense {Boswellia carterii). Finally, fatigue was usually treated with rosemary 
{Rosmarinus officinalis) and lemon {Citrus limonum). 
Lavender {Lavandula angustifolia) 
Lavender {Lavandula angustifolia, [La]) was generally regarded as safe (GRAS), 
but allergies to lavender have occurred (EOPR, 2004). Prashar, Locke and Evans (2004) 
reported evidence that linalool, a major component of lavender EO, may be cytotoxic to 
human skin cells. La, chiefly composed of linalyl acetate (51%) and linalool (35%), 
acted as potential irritants; allergenic skin reactions with proposed membrane damage as 
the possible mechanism of action. Linalool was identified as the active component of La. 
Linalyl acetate cytotoxicity was higher than the oil, suggesting suppression of its activity 
by an unknown factor in the oil. Linalool and linalyl acetate were rapidly detected and 
absorbed into skin after a massage, reaching peak levels after 19 minutes (Jager, et al. 
1992). 
Battaglia (2003) identified the therapeutic actions of La as: analgesic, 
anticonvulsive, antispasmodic, antidepressant, antispasmodic, antimicrobial, carminative, 
decongestant, deodorant, diuretic, emmenagogue, hypotensive, nervine, and sedative. 
Recent research has added even more categories to this list. 
Analgesic Properties 
Lavender EO has been studied for pain relief; relaxation with anti-inflammatory 
and cell regenerating properties. It has been applied neat or undiluted to the skin (Enteen, 
2005). Several studies have demonstrated La's abilities to alter pain perceptions. Kim, 
Wajda, Cuff, Serota, Schlame, and Axelrod, et al. (2006) reported a RCT study of 50 
patients' post-operative (postop) course after undergoing breast biopsy surgery. The 
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control group (n = 25) received standard postop care, supplemental oxygen (O2) through 
a face mask, while the experimental group (n = 25) was given 2 drops of 2% La through a 
face mask postop with the oxygen. Outcomes did not significantly affect pain scores, 
narcotic requirements or recovery discharge times, but those with La reported a higher 
satisfaction rate with pain management than the control group (p = 0.0001). 
A gender balanced, randomized crossover design using pretest/posttest VAS 
measurements on 13 men and women evaluated results on physical parameters after 
separate inhalation treatments of lavender, rosemary, and distilled water. Aromatherapy 
did not elicit a direct analgesic effect, but altered the affective appraisal of the experience 
and subsequent retrospective treatment evaluations of pain (Gedney, Glover, & Fillingim, 
2004). 
Anesthetic Properties 
Rabbit conjunctival reflex tests were completed with La, linalyl acetate and 
linalool. La was administered into the conjunctival sac. A dose-dependent increase in the 
number of stimuli necessary to provoke the reflex resulted. This supported in vivo local 
anesthetic activity (Ghelardini, Galeotti, Salvatore, & Mazzanti, 1999). 
Antispasmotic Properties 
La has been used to relieve muscle spasm, sprain, strain, cramp, contracture and 
rheumatic pain. Too much lavender, however, can be as stimulating as a cup of espresso 
(Enteen, 2005). 
Sedative and Anticonvulsant Properties 
Lavender's sedative effects compare to valium (Buckle, 2000). Harris (2008) 
reports La's gamma-aminobutyric acid (GABA) activity, similar to benzodiazepine. La 
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is also an inhibitor of glutamatergic transmission in the brain with comparative effect to 
the barbiturate phenobarbital thus supporting sedative, hypnotic and anticonvulsant 
properties (Harris). Concomitant use with drugs that act on GABA or glutamate 
neurotransmitters might compete at the ligand binding sites or enhance sedation (Harris). 
Interaction probably depends on the administration route and absorbed dose. 
Inhaled La significantly slowed activity in mice related to exposure time 
(Buchbauer, Jirovetz, Jager, Dietrich, & Plank, 1991). Mice fed a 1.6% dilution of La 
significantly increased sedative effects of pentobarbital by increasing sleep time 
(Guillemain, Rousseau, & Delaveau, 1989). Other in vivo animal studies suggested that 
La had anticonvulsive, sedative, and antispasmodic activities (Gilani, Aziz, Khan, 
Shaheen, Siddiqui, & Herzig (2000). 
Effects on Sleep 
Lavender is a CNS sedative relieving HA, nervous tension, and insomnia (Enteen, 
2005). It helps balance mood swings (Enteen). Lavender is also useful as a nocturnal 
sedative in elderly patients (Hudson, 1996). 
Masago, Matsuda, Kikuchi, Miyazaki, Iwanaga, & Harada, et al. (2000) reported 
changes on an electroencephalogram (EEG). Parietal and posterior temporal EEG re-
gions demonstrated significant decrease in alpha 1 (8-10 Hz) soon after the onset of La 
inhalation (p < 0.01). There may be a correlation between alpha 1 activity and subjective 
evaluation. 
Olfactory stimulus sleep effects were studied on 31 healthy sleepers of 18 - 30 
years of age. They completed 3 consecutive overnight sessions in a sleep lab 
experiencing an intermittent presentation of 2 minutes of the La with 10 minute intervals 
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or distilled water. Polysomnographic sleep and self-rated sleepiness and mood data were 
collected. Lavender increased the percentage of slow-wave sleep (SWS) in men and 
women. All subjects reported higher morning vigor after lavender exposure, 
corroborating the SWS increase. Females showed increased stage 2 (light) sleep, and 
decreased rapid eye movement (REM) and time taken to wake after first falling asleep in 
females (n = 15) with opposite effects in males (n = 16) (Goel, Kim, & Lao, 2005). 
Anti-Stress and Anxiolytic Properties 
Lavender EO sachets reduced test-taking stress in graduate nursing students as 
evidenced by lower scores on test anxiety measure, personal statements, and pulse rates 
(McCaffrey, Thomas, & Kinzelman, 2009). Inhalation of lavender for 3 minutes 
increased alpha power of an EEG as anxiety decreased bringing about a comfortable 
feeling and a better mood (Diego, Jones, Field, Hernandez-Reif, Schanberg, & Kuhn, et 
al., 1998; Masago, et al., 2000). 
Ambient lavender reduced anxiety and improved mood in patients waiting for 
dental treatment. The sample consisted of 200 patients with equal gender distribution. 
Ages ranged between 18 and 77 years (Lehrner, Marwinski, Lehr, Deecke, & Deecke, 
2005). 
Fourteen female chronic hemodialysis patients were studied for mood and anxiety 
using lavender aroma. Effects were measured using the Hamilton scale for depression 
(HAMD) and the Hamilton scale for anxiety (HAMA). Lavender EO was not found to 
significantly decrease depression, but significantly decreased mean scores for anxiety as 




Lavender is a tonic to the cardiovascular and gastrointestinal (GI) systems. It 
lowers blood pressure (Enteen, 2005). A 10 minute, hot La foot bath appeared to be 
associated with small, but significant changes in autonomic activity (Saeki, 2003). La 
produced an increased finger-tip blood flow, decreased galvanic skin resistance and 
systolic blood pressure (Satoko & Yuka, 2000). 
Anti-Allergenic Properties 
Cell-mediated immediate-type allergic reactions were tested by putting lavender 
EO on and under the skin of mice. Allergic reactions by mast-cell degranulation were 
inhibited (Kin & Cho, 1999). 
Antimicrobial Properties 
Nelson (1997) reported that La was effective against 15 strains of methicillin 
resistant Staphylococcus aureus (MRSA) and 5 strains of vancomycin resistant 
enterococcus (VRE). Effective dilutions were one lower than tea tree. 
Lavender shows fungistatic and fungicidal activity against Candida albican 
strains. Lower concentrations inhibit germ tube formation and hyphal elongations and 
may reduce fungal progression or spread of infection (D'Auria, Tecca, Strippoli, 
Salvatore, Battinelli, & Mazzanti, 2005). 
Antimutagenic Properties 
Reports of mutagenic and antimutagenic properties are now surfacing for EOs. 
Lavender shows promising antimutagenic properties on bacterial strains of Salmonella 




Multiple studies conducted to control agitation associated with dementia 
concluded that Lavender may relieve dementia's agitation (Holmes, Hopkins, Hensford, 
MacLaughlin, Wilkinson, & Rosenvinge (2002). Patients with severe dementia in a LTC 
unit were recruited for a study with EOs. A communal area for 15 patients was diffused 
with 2% lavender oil steam for 2 hour periods alternating with placebo (water) for 10 
treatments every other day. Results showed that agitated behavior significantly improved 
for 9 patients (60%); 5 patients (33%) showed no change; 1 patient (7%) became worse 
during aromatherapy compared to placebo (Holmes, et al.). 
Cross-over studies of randomized trials for Chinese older adults with dementia 
using lavender inhalation tested with Chinese versions of Cohen-Mansfield Agitation 
Inventory (CCMAI) and Neuropsychiatric Inventory (CNPI) showed significant 
decreases after receiving lavender. CCMAI total scores decreased from 14.68-17.77 
(f=10.79, df= 69, p < 0.001). The CNPI scores changed from 63.17 (SD = 17.81) to 
58.77 (SD = 16.74); (t = 14.59, df= 69, p< 0.001). There was no period or sequential 
effects noted. Lavender was effective as an adjunctive therapy to alleviate agitated 
behaviors in Chinese patients with dementia (Lin, Chan, Ng, & Lam, 2007). 
Anticoagulant Properties 
Ballabeni, Tognolini, Chiavarini, Impicciatore, Bruni, Bianchi, et al., 2004 re-
ported initial in vitro evidence that lavender's synergistic components had effects of 
antiplatelet/antithrombotic properties. The coumarins in lavender helped thin blood 
(Enteen, 2005). 
Basil {Ocimum basilicum) 
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Basil is an aromatic, medicinal plant used in ancient Indian medicine for ailments 
such as muscle cramps, pain, insecticidal, anti-ulcer, anti-inflammatory, diabetes and 
respiratory tract problems (Abas, Lajis, Israf, Khozirah, & Kalsom, 2006: Chaha, Eze, 
Emuelosi, & Esimone, 2006; Keita, Vincent, Schmidt, Arnason, & Belanger, 2001; 
McClatchey, 1996; Pushpangadan & Sobti, 1977). Basil EO is GRAS (EOPR, 2004) 
and demonstrates strong bactericidal properties against Aeromonas hydrophilia and 
Pseudomonas fluorescens (Wan, Wilcock, & Coventry, 1998). 
Anti-Inflammatory Properties 
Basil is an anti-inflammatory, antimicrobial, antispasmodic EO that relaxes 
muscles (EOPR, 2004). Basil is an external analgesic in massage oil formulas to ease 
tension in muscles and tendons (Rose, 2006). Dwivedi, Rahul, and Chaturvedi (2010) 
recommend basil for muscular pain, colds, depression, and fatigue. 
Singh (1999) reported anti-inflammatory activity in rats using basil EO. Mice and 
rat models showed that basil EO showed antinociceptive effects, antibacterial effects 
against multidrug resistance, and anti-ulcer properties (Opalchenovaa & Obreshkovab, 
2003; Rabelo, Souza, Soares, Miranda, Matos, & Criddle, 2003; Singh). 
An anti-inflammatory activity of crude extracts of Ocimum basilicun using peri-
pheral blood mononuclear cells (PBMC) of healthy individuals showed a significant in-
hibitory effect (78% of crude methanolic extract at 30 ng/mL) on proliferative response 
of PBMC in mitogenic lymphocyte proliferation assays. Basil down-regulated proin-
flammatory cytokines like tumor necrosis factor-a (TNF- a), Interleukin-lp (IL-1B) and 
Interleukin-2 (IL-2). Basil also suppressed the induction of inducible nitric oxide syn-
thase (iNOS) and subsequent production of nitric oxide (NO). Results showed that basil 
methanolic extract inhibits key proinflammatory cytokines; mediators, and accounts for 
anti-inflammatory effect (Selvakkumar, Gayathri, Vinaykumar, Lakshmi, & 
Balakrishnan, 2007). 
Peppermint {Mentha x piperita) 
Peppermint is a perennial flowering member of the mint family (Schelz, 
Hohmann, & Molnar, 2010) extracted from the plant's stems, leaves and flowers (Kligler 
& Chaudhary, 2007). Peppermint EO is GRAS (EOPR, 2004); a carminative (Sego, 
2008). 
Current use of peppermint EO had roots in Ancient Greece. It was used as an 
internal medicine for digestive aid, management of gallbladder disease, treatment of 
upper respiratory diseases and coughs (Schelz, et al, 2010). 
Kligler and Chaudhary (2007) reported that peppermint oil was well tolerated in 
common doses, but may cause significant adverse effects at higher doses. Full-doses 
were not recommended for patients with hiatal hernia, severe gastroesophageal reflux, 
gallbladder disorders, pregnant or lactating women (Kligler & Chaudhary). Common 
side effects were topical allergic dermatitis associated to menthol sensitivity which re-
solves with cessation, chronic urticaria 'hot flashes' and GI irritation (Sego, 2008; Woolf, 
1999). 
Antispasmodic Properties 
Active ingredients in peppermint EO include menthol, menthone, cineol, and 
other volatile oils (Blumenthal, 2000). Menthol is commonly seen in OTC topical 
products for respiratory congestion, HA and muscle pain. Peppermint is effective in 
relaxing GI smooth muscle, possibly through calcium channel blocking on a local level in 
49 
the gut resulting in smooth muscle relaxation (Hills & Aaronson, 1991; Micklefield, 
Greving, & May, 2000; Schelz, et al., 2010; Taylor, Luscombe, & Duthie, 1983, 1984). 
It also relaxes the lower esophageal sphincter, which can result in gastroesophageal reflex 
(Brinker, 1998). Peppermint seems to alleviate symptoms in functional somatic disorders 
like IBS, FM, and chronic fatigue syndrome, (Grigoleit & Grigoleit, 2005; Logan & 
Beaulne, 2002). 
Peppermint EO has inconsistent or limited-quality patient-oriented evidence as a 
safe alternative for reducing symptoms of irritable bowel syndrome (IBS) with enteric-
coated peppermint oil (Lawson, Knight, Tran, Walker, Roberts-Thompson, 1988; Logan 
& Beaulne, 2002; Spanier, Howden, & Jones, 2003). Peppermint has also been used for 
non-ulcer dyspepsia; relieving some IBS symptoms (Pittler & Ernst, 1998). In combina-
tion with caraway oil, peppermint EO has been used for reducing symptoms of non-ulcer 
dyspepsia (Holtmann, Haag, Adam, Funk, Wieland, & Heydenreich, 2003; Madisch, 
Holtmann, Mayr, Vinson, & Hotz, 2004). 
Analgesic Properties 
Topical applications of peppermint EO are claimed to effectively treat tension 
HAs (Gobel, Fresenius, Heinze, Dworschak, & Soyka, 1996; Kligler & Chaudhary, 
2007). Several research studies support this claim. 
Gobel, Schmidt, and Soyka (1994) studied 32 healthy subjects in a double-blind 
crossover, placebo-controlled, randomized trial. Eucalyptus, peppermint and ethanol 
were tested in 4 preparations. Combinations of eucalyptus, peppermint and ethanol in-
creased cognitive performance with muscle and mental relaxing effects, but little influ-
ence on pain. There was a significant decrease in HAs with peppermint and ethanol. 
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Gobel, Fresenius, and Heinze (1996) studied local applications of 10% peppermint 
EO to test effects on 164 tension HAs in 41 people between the ages of 18 and 65 years. 
A double-blind, crossover, placebo-controlled, randomized trial was completed measur-
ing pain recorded in a self-reported diary log. Results were significant and equal to the 
efficacy of acetaminophen 1 gram (p < .01). Peppermint significantly decreased pain 
after 15 minutes compared to the placebo (p < .01) which continued over a one hour 
observation period. 
Peppermint enhances the effects of other EOs. It has analgesic and antimicrobial 
properties, stimulates circulation and cools inflamed tissue (EOPR, 2004). 
Antimicrobial, Antiemetic, and Anti-Allergenic Properties 
In vitro, peppermint was effective against 15 strains of MRS A; 5 strains of VRE 
at one dilution lower than tea tree (Nelson, 1997). Peppermint decreased postop nausea 
with less traditional use of antiemetics (Tate, 1997). Six flavonoid glycosides have been 
identified in peppermint EO, compound 4 showing a potent inhibitory effect on histamine 
release induced by antigen-antibody reactions in rats (Inoue, Sugimoto, Masuda, Kamei, 
2001). 
Tea Tree {Melaleuca alternifolia) 
Australian tea tree {Melaleuca alternifolia, [Ma]) grows in the low swampy coast 
of New South Wales in Australia; it does not grow naturally outside Australia. 
Originally, the plant was used by aboriginals for coughs and colds (Schelz, et al., 2010). 
Antimicrobial Properties 
Tea tree oil (Ma), is a broad-spectrum antimicrobial agent, (Messager, Hammer, 
Carsen, & Riley, 2005; Papadopoulos, Carson, Hammer, & Riley, 2006; Schelz, et al., 
51 
2010) with strong antibacterial activity against periodontopathic and cariogenic bacteria 
(Takarada, Kimizuka, Takahashi, Honma, Okuda & Kato, 2004). Ma efficiently killed 
Staphylococcus aureus in the stationary growth phase and with biofilms (Kwiecifjski, 
Eick, & Wojcik, 2008). In vitro, Ma was potent against 15 strains of MRSA and 5 strains 
of VRE (Nelson, 1997). 
Ma demonstrated inhibitory and fungicidal activity (Hammer, Carson, & Riley, 
2000, 2002). Components showing the most fungicidal activity with minimum inhibitory 
concentrations (mic) were terpinen-4-ol, a-terpineol, linalool, a-pinene and P-pinene, 
followed by 1.8-cineole (Hammer, Carson, Riley, 2003). 
Eucalyptus (Eucalyptus globulus) 
Eucalyptus globulus Labill. (Myrtaceae) EO is rich in cineole and obtained 
through steam distillation of the leaves (Arctander, 1960; Garg, 2005). Eucalyptus is 
rapidly absorbed. The active ingredient, eucalyptol, is made of 1.8 cineole plus tannins; 
capable of hepatic microsomal induction that may affect the metabolism of other drugs 
and chemicals. The cinele-monoterpenol synergy found in EO treats viral pathologies of 
the respiratory tract (Baudoux, 2005). This synergy can be found in many EOs that come 
from trees of the Myrteceae family, like eucalyptus. 
"Eucalyptus globulus is an Approved Herb used for catarrhs of the respiratory 
tract (internal and external application) and externally for rheumatic complaints" with 
actions listed as "secretomotory, expectorant, mildly antispasmotic and mild local 
hyperaemic" (Lis-Balchin, 2006, p. 185). The rich cineole creates antibacterial, 
antifungal, antiviral, anticatarrhal, mucolytic, expectorant and antidepressant properties 
(Garg, 2005) and can also act as a decongestant and stimulant (Dwivedi, et al., 2010). 
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Lis-Bachin reports a wide range of use for Eucalyptus globulus (E. globulus) including 
decongestion, asthma, bronchitis, and emphysema (with infection), catarrh coughs, 
whooping coughs, tuberculosis, tonsillitis, sinusitis, nose, ear, and throat infections. 
Eucalyptus EOs are ingredients in inhalants, liniments, and Vicks® ointment for 
respiratory and muscular problems (Garg, 2005). Eucalyptus EO products for rhinitis and 
chronic associated symptoms are usually OTC; not regulated by the Federal Drug 
Administration (FDA). 
Lis-Balchin (2006) reports that E. globulus and Eucalyptus radiata (E. radiata) 
tested at 10% showed nil effect on irritation and sensitization, though hypersensitivity for 
E. globulus has been reported. There has been no phototoxicity reported (Lis-Balchin). 
External applications on humans is considered generally non-sensitizing, non-toxic, and 
non-phototoxic (Tisserand & Balacs, 1995). "Undiluted eucalyptus oil is toxic and 
should and should not be taken internally" (Lis-Balchin, p. 186). 
Neurotoxicity is reported especially with oral ingestion/aspiration including 
miosis, weakness, headache, ataxia, seizures, coma and death (Melis, Bochner, & 
Janssens, 1989; Spoerke, Vanderberg, Smolinske, Kulig, & Rumack, 1989). Toxicity and 
complications are more frequently reported in children (Woolf, 1999). 
Research Studies 
Ciliary beat frequency (CBF) of nasal mucosa in vivo was tested using sesame, 
soy, peanut, thyme, lavender, eucalyptus oils and menthol at 0.2% and 2% concentrations 
(Nehr, et al., 2008). Thyme oil was ineffective, peanut oil was the strongest and all other 
oils resulted in an increased CBF strongest at the 0.2% concentration (Nehr, et al.). 
Galdi, Perfetti, Calcagno, Marcorulli, & Moscato (2003) reported a case study of a 
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30 year old woman with asthma and rhinoconjunctivitis with exacerbated asthma from 
exposure to eucalyptus pollens while camping and by ingestion of an infusion containing 
eucalyptus. The composition of the eucalyptus infusion was not specified. Juergens 
(2001) proposed eucalyptus oil to treat bronchial asthma and respiratory diseases. 
Eucalyptus was also reported as an etiology to urticaria (Vidal & Calbeza, 1992), contact 
dermatitis and airborne contact dermatitis (Schaller & Korting, 1995). Minero and 
Fernandez-Mensaque (1994) consider eucalyptus pollens a potential cause of allergy. 
Burkhard, Darben, Cominos, and Lee (1998) reported that a 6 year old girl 
developed slurred speech and muscle weakness becoming unconscious when eucalyptus 
oil was rubbed on much of her body for an itch rash. Once the ointment was removed, 
she recovered without long term sequelae. 
Essential Oil Literature Review Summary 
EOs have been used throughout ancient times for medicinal properties. La, basil, 
and peppermint EOs have been GRAS. Allergies have been reported with EO use. 
Lavender, a universal EO, has been researched most extensively with reports of 
sedative qualities from GABA activity similar to benzodiazepine. La has demonstrated 
anxiolytic, anti-stress, antidepressant, anti-conflict, and anti-agitation properties. 
Lavender has altered the perceptions of pain. Several studies have demonstrated effects 
on EEG patterns and sleep facilitation. Other reports have shown antimicrobial 
properties against MRSA, VRE and Candida albicans. Lavender also has demonstrated 
antimutagenic properties. Another study has demonstrated anticoagulation properties. 
Basil is an antispasmodic, anti-inflammatory EO which acts as an antinociceptive 
agent. Basil down-regulates proinflammatory cytokines and is used for sore muscles. 
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Peppermint, another universal EO, relaxes smooth muscles in the GI system. It 
also relaxes the lower esophageal sphincter. Studies show significant efficacy in 
analgesic properties at 10% concentrations equal to acetaminophen one gram. Also, 
peppermint shows antimicrobial, antiemetic, anti-allergenic properties, and for upper 
respiratory infections. 
Tee tree is a powerful, broad antimicrobial agent. It effectively inhibits MRSA 
and VRE in low concentrations. Tee tree also has strong fungicidal properties. 
Eucalyptus supports the upper respiratory system. It is a mucolytic, decongestant 
and expectorant. Eucalyptus properties include antiviral, antibacterial and antifungal. 
Critique of Essential Oils, Research Findings 
Inconsistent research designs and methodologies made EO study results difficult 
to evaluate and validate, perhaps contributing to failed outcomes. Many studies were 
unclear about EO species, therapeutic grades, dose or percentages administered to 
interpret accurate results. Studies working with multiple oils failed to establish clear 
individual responses to EOs. Small sampled numbers contributed to insufficient power 
needed to attain statistically significant results. Scientific thought places a great value on 
the randomized clinical trial (RCT); authorities state that RCTs are desirable in CAM 
therapy studies (Ernst, 2002). Yet, multicentered, double-blinded, longitudinal RCTs 
with meta-analysis rarely, if ever, were found to establish credible treatment options in a 
western allopathic society. 
Conclusion 
Given the current state of scientific knowledge regarding the use of essential oils, 
it was appropriate to undertake a descriptive and contextual approach in the examination 
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of their use in such a complex entity as fibromyalgia. This study was designed to meet 
the critical need for an enriched understanding of the context in which individuals 
perform self-care using essential oils for fibromyalgia. 
Chapter three, methods, describes the research plan for this CSR approach. It 
goes into more detail on research design and data collection procedures. 
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Chapter 3 Methods 
A single, case study best answers the questions of 'how' and 'why' an individual 
uses EOs to manage chronic symptoms as well as the outcomes of their use. Chapter 3 
includes: 1) research purpose and questions; 2) research design; 3) setting and sample; 4) 
units of analysis; 5) data collection procedures; 6) data management and analysis; and 7) 
strengths and limitations of the proposed study. 
Research Purpose and Questions 
This feasibility study used the single case study research (CSR) embedded 
method developed by Yin (2009). The overall purpose of this evaluative, descriptive 
research was to explore proposed causal links in the self-care (SC) use of essential oils 
(EOs) over several years to mitigate chronic symptoms associated with fibromyalgia 
(FM) within context reality. 
The specific aims of this single, embedded CSR was to explore 'how' and 'why' 
the informant, who suffered from FM, chose to initiate self-care (SC) with essential oils 
(EOs) and continue this regimen over several years. This study addressed the following 
questions: 
1. How and why did the informant use essential oils in self-care? 
2. How and why did the informant self-manage chronic symptoms of fibromyalgia 
using other aspects of integrative medicine besides essential oils? 
3. How and why did essential oil self-management intervention help the informant 
maintain function and activities of daily living? 
4. How did the informant integrate self-care management with essential oils, their 
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use, effects, and outcomes into the context of her daily life? 
Research Design 
This was an indepth, single case, embedded, research design. "A single-case 
study is analogous to a single experiment, and many of the same conditions that justify a 
single experiment also justify a single-case study" (Yin, 2009, p. 47). Yin cited 5 ration-
ales to conduct a single case study. The chosen unit of analysis, an individual informant 
with a chronic condition of FM, met two of these 5 rationales. 
First, this research study represented an extreme or unique case (Yin, 2009). 
Women experiencing FM used varied treatments simultaneously with fluctuating effects. 
Literature reviews did not, however, reveal information related to continuous and pro-
longed self-administration of EOs or the reality context of their use on chronic symptoms 
associated with FM. The majority of in vivo research studies failed to identify the speci-
fic EO's name, dose, frequency, and/or duration of use to reproduce reported outcomes. 
This case study presented an opportunity to report indepth information on the SC use of 
EOs within the lived context of chronic illness associated symptoms, self-management 
interventions (SMI), and outcomes. 
Secondly, this study represented a revelatory case or a rare study opportunity 
(Yin, 2009). This researcher observed and analyzed the use of EOs as a SC phenomenon 
and their implementation into a self-care management (SCM) program for chronic symp-
toms associated with FM. The reliable informant was known to the researcher. The EOs 
used were medicinal grade with good purity and quality. This provided an extremely rare 
opportunity to analyze outcomes of these EOs used for SCM of chronic symptoms. 
Single Case Study Analysis 
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The researcher collected relevant data to study the global phenomenon of SC in-
tervention/SM within the informant's lived experience of the chronic symptoms of FM. 
Analyzed data included an indepth, qualitative informant interview, the informant's medi-
cal records, literature reviews, and Likert visual analog scale (VAS) using a zero (lowest 
point) to 10 (highest point) that measured symptom severities, functional impact, and the 
efficacy of EOs. Thus, the investigator collected and analyzed descriptive, quantitative, 
and qualitative data. 
Setting and Sample 
The case unit of analysis was an economically self-supporting, single 56 year old 
female. Sandi was a public high school math teacher who lived with a dog in a single 
level home. She used medicinal grade EOs for several years as a component of her SC 
interventions (SCI) and SM program for FM. The informant's behaviors, self-agency, 
and perceptions of using self-applied EOs to control chronic symptoms for health and 
well-being constituted the phenomenon of study. 
Measures 
Four Likert VASs (0 = lowest score; 10 = highest score) collected information. 
The Chronic Symptom Frequency (Appendix D), Chronic Symptom Severity (Appendix 
E) and EO Efficacy (Appendix G) Scales consisted of the same 29 questions based on 
literature findings. The Function and Activities of Daily Living Scale (Appendix F) 
originally consisted of 25 questions, but one was inadvertently repeated. Therefore, this 
scale consisted of 24 items. The informant needed clarification of directions on the 
severity scale and a 30 minute intermission between the second and third VAS 
completion. Additional brief comments were added by the informant at her discretion 
under the VAS statements in the Chronic Symptom Frequency Scale and the Essential 
Oil Efficacy Scale. This additional information was analyzed for clarity and indepth 
comprehension of the VAS data. The VAS data collection was completed on 02/26/11. 
The indepth, audiotaped interview occurred on 02/27/11 per informant's request 
in her home setting. The interview time totaled approximately 110 minutes answering 
questions on how the informant used EOs for the SCM of chronic FM symptoms. Ques-
tions (Appendix H) and interview information were grouped into the inception of SC 
practice, SC practice: midpoint, and the currently lived SC experience to understand the 
use of EOs within the lived context of FM and the evolution of SCM. 
Eleven rheumatology visits were analyzed for FM diagnosis, symptom clusters 
and treatment approaches. The informant's medical history and comorbidities informed 
findings. Medical records were analyzed for FM symptom clusters, treatments, and med-
ical recommendations. Per Sandi, the rheumatologist requested results of this study in 
the hope of helping other FM patients. Rheumatology records were dated from October 
of 2006 through November of 2010. 
Research field notes maintained and documented communications with the infor-
mant before, during and after data collection. They noted method deviation(s), study 
revisions, reflections/insights, and/or future CSR design recommendations. Field notes 
clarified data and chains of evidence. 
Field observations verified the informant's active lifestyle and the exacerbation of 
FM symptoms that resulted in functional decline. Observations clarified the integration 
of EOs and multimodal SCIs into Sandi's daily routine. The researcher observed the 
storage, applications and outcomes of the use of EOS and other SMI within the lived 
experience of FM. 
Embedded Units of Analysis 
Embedded units provided a complete and thorough data analysis to study the 
global phenomenon of SCI/SMI within the informant's lived experience. The 3 embed-
ded units of analysis within this case study included chronic FM symptoms, SC and EOs. 
The literature findings were analyzed within each embedded unit. This also provided de-
tailed perspectives to help establish the CSR's chain of evidence. 
Chronic Symptoms of Fibromyalgia 
The first embedded unit of analysis was chronic symptoms experienced through 
Sandi's lived context of FM. This investigation included a literature review identifying 
common symptoms associated with FM. Data collection from the informant included an 
indepth qualitative interview as well as quantitative Likert Visual Analog Scales (VASs) 
to specify and quantify onset, location, duration, characteristics, aggravating, alleviating, 
relieving, treatments tried, and the severity of each symptom. The informant provided 
her rheumatologic medical records (MRs) for further data analysis related to symptom 
clusters. Field notes and observations verified functional declines with symptom 
exacerbation and triggers. 
Self-Care 
Chronic symptom SCM was the second embedded unit of analysis. Analysis 
included a literature review of FM to highlight in vivo SC treatment modalities and 
patterns. Pain intensity and the impact of FM on functional status were the most common 
variables in FM research (Rooks, 2007). The VAS was typically anchored by extremes 
of the characteristic being assessed (Rooks). Zero would indicate the absence of pain and 
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the other anchor would indicate the most pain ever experienced. Other common symp-
toms assessed with the VAS scale included general fatigue, tiredness upon awakening, 
sleep, and mood (Burckhardt, et al., 1994). Depression, anxiety, and sleep disorders were 
addressed independently of FMS symptoms (Rooks). 
For this CSR, Likert VASs clarified the informant's self-reported levels of 
symptom frequency, severity and functional status. An indepth audiotaped informant 
interview reported integrative management modalities within her lived context. The 
interview included the informant's self-perceptions of FM; SC processes focused on 
'how' and 'why' EOs as SMI were initiated and maintained over several years. Data 
included the informant's self-perceived efficacy of multimodal treatments utilized 
individually or in combinations to manage chronic symptoms. Field notes and 
observations provided further clarification, verification, and enriched understanding of 
the lived context of SCI/SCM. 
Essential Oils 
The third embedded unit of analysis was the use of EOs. Data included an 
extensive literature review, indepth informant interview, EO Efficacy VAS, the 
researcher's field notes and observations, and the rheumatology MRs. Reports included 
specific names, mixtures, grades, analysis, and storage methods of the informant's EOs. 
Collected data included EO doses, mixtures, frequencies, routes, locations, and 
administration methods. The effects of EOs from the literature review were discussed as 
well as the informant's self perception of chronic symptom management efficacy. Field 
notes and observations provided further clarification, verification, and enriched 
understanding of how EOs were stored, applied and used to treat FM symptoms with 
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resulting outcomes. 
Data Collection Procedures 
After obtaining research approval through the University of San Diego's 
Institutional Review Board (IRB) (Appendix B), the informant verbally consented over 
the phone to participate in the research study. Written consent (Appendix C) and the 
initiation of data collection were verbally agreed upon and scheduled for Saturday, 
2/26/11 at the informant's private home. Sandi agreed to obtain MRs from the 
rheumatologist who supported research participation providing MRs without cost. 
Informed Consent and Human Confidentiality 
The CSR process was discussed with the informant. Possible negative effects 
were reviewed including fatigue, pain, feelings of sadness and loss during the recollection 
of the lived context of her diagnosis and chronic symptom management struggles. The 
informant was told that she could terminate participation in the research protocol at any 
time, refuse to answer uncomfortable questions; modify the data collection schedule to 
accommodate her personal physical and/or emotional needs without negative ramifica-
tions. After a brief discussion with only process oriented questions and answers 
(addressed later within this chapter), the researcher obtained written, informed consent 
including audio taping during the indepth interview. The informant received a copy of 
the informed consent. 
Confidentiality was maintained by using a pseudonym (Sandi) for reporting 
purposes. Her geographic location was not revealed. The informant understood and 
accepted the risk that she could still be identified in the single case research design. Data 
were secured at all times. Only the researcher, transcriptionist, informant and the 
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researcher's dissertation chairperson had access to the data. 
Data Collection Study Protocols 
The completion of all Likert VAS forms, an audiotaped indepth interview and 
field observations were mutually agreed upon and completed at the informant's private 
home setting to maintain her comfort and confidentiality. Sandi requested that the Likert 
VAS use 0.5 increment intervals so that she could more accurately rank her FM symptom 
frequency, severity, functional status and the efficacy of the EOs. The researcher 
assented. Also, the informant requested that due to her busy schedules, data collection be 
completed within the available weekend (2/26/11 - 2/27/11). The researcher assented. 
First Research Visit 
During the first research session (02/26/11), the investigator explained the study, 
research confidentiality, addressed any study concerns, and answered the informant's 
question(s). After this was completed, written, informed consent was obtained. Comple-
tion of the Likert VASs occurred in the following order: Chronic Symptom Frequency 
Scale, Chronic Symptom Severity Scale, Function and ADL Scale, and Essential Oil 
Efficacy Scale. After the informant completed the Likert VASs, results were reviewed 
with the informant to ensure thoroughness and clarity. Field notes were maintained and 
informant comments were documented. Likert reviews were not recorded, but field notes 
and observations were maintained. 
The informant needed a break after the third VAS form was completed due to 
complaints of right arm, shoulder and neck pain initiated from repetitive writing actions. 
She also complained of the room feeling "cold" and changed into warmer clothes. After 
applying 2-3 gtts of basil and peppermint EO neat (direct; undiluted) to these areas for 
pain management and a cup of tea, Sandi was comfortable to continue data collection. 
She requested that the researcher document her answers on the EO Efficacy Scale so that 
pain would not flare back. The researcher assented. 
Post First Research Visit 
The researcher analyzed outcomes of Likert VASs using descriptive statistics. 
Data was analyzed into themes and patterns (Yin, 2009). Field notes were reviewed for 
further clarification prior to the indepth informant interview. This provided further 
guidance to additional questions needed to complete the global and comprehensive data 
collection. 
Second Research Visit 
The indepth interview was completed the day after the Visual Analog Scales 
(VAS) instead of a week later per original protocol. During the second research session, 
which occurred on 02/27/11, the investigator met with Sandi to complete a private, 
indepth interview (Appendix F). This interview was timed and audiotaped. Questions 
were asked encompassing the 3 embedded case study units within the chronological time 
reference of treatment inception, midpoint (approximately one year later), and current SC 
status. Break times were not needed. Field notes were later recorded to clarify post dis-
cussions with the informant. 
Post Second Research Visit 
After written confidentiality was obtained, audiotaped interactions were 
transcribed verbatim by a transcriptionist for data analysis. Field notes were analyzed for 
further research clarification and to provide details. The investigator reviewed 
transcripts. Copies of transcripts and completed VASs were mailed to the informant for 
final revisions, edits, and or verification. Verification and clarification of content were 
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obtained by phone one week after the informant received the data. Final approval of 
context, meaning and content were obtained by the informant at 2130 on 03/21/11. 
Chapter 4 analyzes data and reports the CSR results. Final analysis results 
construct a linked chain of evidence within embedded units of analysis to answer the 
'how' and 'why' of all original research questions. Global and holistic conclusions 
summarize the aim of the research study. 
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Chapter 4 Results 
Introduction 
The single overall purpose of this evaluative, descriptive research was to explore 
proposed causal links in the self-care (SC) use of essential oils (EOs) over several years 
to mitigate chronic symptoms associated with fibromyalgia (FM) within context reality. 
The specific aims of this single, embedded case study research (CSR) was to explore 
'how' and 'why' the FM informant chose to initiate SC with EOs continuing this regimen 
for several years. Specifically, this study addressed the following questions: 
1. How and why did the informant use essential oils in self-care? 
2. How and why did the informant self-manage chronic symptoms of fibromy-
algia using other aspects of integrative medicine besides essential oils? 
3. How and why did essential oil self-management intervention help the 
informant maintain function and activities of daily living? 
4. How did the informant integrate self-care management with essential oils their 
use, effects, and outcomes into the context of her daily life? 
Sample 
The sample for this CSR design was a 56 year old single, self-supporting female 
Caucasian informant educated at the masters level. Sandi, a public school mathematic 
high school teacher lived with a dog, never married, or had children. She was well-
connected with social support systems, local family members and many friends. 
Data Analysis 
Data included results of 4 Visual Analog Scales (VAS) scales including brief 
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comments on 2 of the 4 VAS scales. Medical records (MRs) from Sandi's 
rheumatologist were analyzed for FM diagnosis, symptom clusters, prescribed 
pharmacologic and nonpharmacologic interventions. Interview transcripts were analyzed 
for the inception of self-care (SC) practice, midpoint SC practice, and the currently lived 
SC experience. To enhance VAS/ interview data analysis, field notes and observations 
were adjuvant identifiers of the lived SC practice experience/rituals. Literature reviews 
were analyzed to corroborate findings. 
Visual Analog Scales 
All VAS consisted of 0 to 10 Likert formats. Per informant's request, scale 
ratings were adjusted to include 0.5 increments to capture data more accurately. The 
Chronic Symptom Frequency, Chronic Symptom Severity, and the Essential Oil Efficacy 
scales consisted of the same 29 items. Significance was attributed to items scored from 7 
to 10. Moderate significance was given to those items scored from 4 to 6.5. Mild 
significance was given to those items scored from 1 to 3.5. 
The Function and Activities of Daily Living Scale consisted of 25 items. Inadver-
tently, "walking" was repeated twice so the final analysis included 24 items. Data were 
analyzed for significance as previously discussed; consistent with the other scales. 
Chronic Symptom Frequency Scale 
The Chronic Symptom Frequency Scale was "hard" for the informant; completed 
in 60 minutes (min). Ten (34.5%) of the 29 research based symptoms were experienced 
daily (Figure 1). Eight (80%) of these 10 daily symptoms were reported at a significant 
frequency. The remaining two (20%) daily symptoms were minimal occurrences. The 
average score for symptoms experienced on a daily basis was significant at 7.25. 
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The remaining 19 (65.5%) of the 29 FM symptoms were not experienced daily. 
Based on the informant's comments, 8 (27.6%) out of the 29 symptoms were experienced 
weekly (Figure 2). Six (20.7%) of the 29 symptoms were reported as monthly 
occurrences (Figure 3). The remaining symptoms were labeled as "sometimes". Instead 
of teary eyes, Sandi's had dry eyes "with shooting pains" which were treated as needed 






































Figure 1: Daily Symptom Frequency in Fibromyalgia 
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Figure 2: Weekly Symptom Frequency in Fibromyalgia 
Figure 3: Monthly Symptom Frequency in Fibromyalgia 
Sinus Congestion 
Comments on the Chronic Symptom Frequency VAS added indepth knowledge of 
etiology, patterns and manifestations. Sinus congestion usually occuned in the late after-
noon without identification of precipitating factors, "could be the weather". Every few 
months, a runny nose lasted "2-3 days". This was not equated to a cold since she "hasn't 
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had colds as often in the last few years" but "more nasal problems like hay fever and 
colds before starting essential oils...using more Benadryl™ and Sudafed™ to treat 
symptoms before" (Field Notes, 2/26/11). The informant "rarely used antihistamines in 
the last 2 years" (Field notes 03/30/11); received annual flu shots. Sandi felt those years 
of teaching had "built up an immunity" noting that "new teachers get sick more often". 
Sinus and Muscular Headaches 
Field notes (2/26/11) stated that sinus HAs occurred about twice weekly. These 
presented, as did muscular HAs and neck pain, "later in the day" or evening; probably 
related to "tiredness and stress". After school activities made pain worse as did repetitive 
actions like writing, bending over her desk, using her arms, computers, and grading 
papers. 
Sensitivity to Touch 
Increased sensitivity to touch occuned "sometimes in certain places". Field notes 
(2/26/11) clarified these as "trigger points: shoulders, knees, and leg tenderness". Sandi 
questioned whether she bumped into something, but "there were no black and blue 
marks". 
Chronic Symptom Severity Scale 
The informant completed the Chronic Symptom Severity Scale in 15 min. Sandi 
needed clarification of directions that modified read "What is the severity of your experi-
ence of these symptoms on a daily basis (24 hour)"? There were no nanative comments 
written. The informant rated all symptoms whether or not they occurred on a daily basis. 
Six (20.7%) of the 29 FM symptoms were reported as moderately severe 
discomfort to severe, consistent discomfort (Figure 4). Three (50%) of the 6 severe 
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symptoms (generalized musculoskeletal pain and discomfort; inegular bowel patterns; 
feeling frustrated because of living with FM) were experienced 80% of the time or more 
as a daily frequency pattern. 
Most, 14 (48.3%) out of 29 of the symptom severity items were rated from 
bothersome to increasing moderate discomfort plus. Finally, 9 (31 %) of the 29 symptom 
severities were rated as minimal. The average severity for VAS items was moderately 
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Figure 6: Moderate Symptom Severity in Fibromyalgia: 2 
''Teary Eyes omitted on figure (0/10) 
Figure 7: Minimal Symptom Severity in Fibromyalgia 
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Function and Activities of Daily Living 
The informant took 10 min to complete this VAS without added comments. Two 
(8%) of the 24 behaviors severely and/or consistently interfered with function. These be-
haviors included gardening, doing outside chores, and/or hobbies. Completing repetitive 
actions resulted in the worse imaginable interference. The majority of behaviors, 14 
(58.3%) out of 24 resulted in a bothersome interference to an increasingly moderate 
interference. 
Instrumental activities of daily living (IADL) showed bothersome to severe and/or 
consistent interference for 16 (43.8%) of 24 behaviors (items 2, 3, 5 - 7, 10, 11, 22-25). 
Seven (43.7%) of the 24 behaviors showed bothersome to the worse imaginable interfer-
ence. One third (8) of the 24 behaviors were rated as minimal to no interference in ADL 
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Figure 10: Functional Limitations from Fibromyalgia: Minimal 
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Essential Oil Efficacy Scale 
Prior to the completion of the last VAS form, the Essential Oil Efficacy Scale, 
Sandi complained of pain in her right arm. She excused herself and left the room to 
transdermally layer undiluted basil and peppermint EOs on the painful areas. She stated 
pain was relieved, but did not want to irritate trigger points further through repetitive 
writing. Sandi requested that the researcher ask EO Efficacy VAS questions, write 
answers and her comments on the form instead of rescheduling the remaining data 
collection. 
Essential oils (EOs) were routinely used by the informant to treat 12 (41.4%) of 
the 29 symptoms. Efficacy ranged from 2 to 9. The average efficacy score of these 13 
items was 6.04 indicating that EOs produced a moderate plus difference/improvement in 
FM symptom relief. The informant was unaware that 16 (55.2%) out of the 29 symptoms 
were associated with FM, therefore, she did not consider the use of EOs to treat these. 
Hip pain was treated with basil EO initially on 2/25/11 resulting in a 3 out of 10 efficacy 
result. 
Six (50%) of the 12 symptoms that were treated with EOs provided significant 
relief (see figure 11). Another 5 (41.7%) of the 12 symptoms were moderately effective 
in relieving FM symptoms using of EOs. The final symptom, heel pain, treated with EOs 
had an efficacy rating of 2 with a severity rating of 3; experienced in her left foot at the 




























































Figure 12: Moderate Essential Oil Efficacy on Fibromyalgia Symptoms 
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Nasal Congestion 
The frequency of nasal congestion was experienced by the informant 95% of the 
time on a daily basis with a moderate discomfort severity. Efficacy depended on the oils 
used. "Diluted oils take longer than full strength. I put them on every 5 to 10 minutes 
until desired effect is achieved". The informant used diluted EOs at school (Appendix 
J). This was a new SC intervention practiced for 3 week duration. 
Sandi uses undiluted EOs applied directly to her skin neat every night before 
sleeping, "neat essential oils work within one to two minutes" and help her "breath better 
with less discomfort". Layering, applying one neat EO at a time, is her "new technique" 
using tea tree followed by peppermint. She is using eucalyptus (for the past 2 weeks) as 
her last layered EO. EO efficacy is a significant plus difference/improvement (8 out of 
10). 
The first drop is applied under her nose so that she can "inhale" the EO; then at 
the "top of her nares". Next, "one drop on each side" of her anterior neck is applied to 
cover her "glands". Finally, EOs are applied on the pre and sometime post auricular 
lymph nodes. In the near future, Sandi plans to mix the "respiratory EOs straight" 
without dilution for use. 
Sinus Congestion 
Undiluted EOs were applied neat, usually at home, for sinus congestion with a 5.5 
efficacy result or slightly more than a moderate difference/improvement. The severity of 
this symptom was rated 6 and experienced 2 - 3 times per week. "I never feel like I 
really have full openings in my nasal passages to fill my lungs". The EOs were diluted in 
the beginning; "didn't think I could do it straight". The informant applied tea tree and 
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peppermint preauricularly, to forehead and upper chest. "I go where I need to with the 
oils, wherever I feel I need them, I put them". 
Runny Nose 
A runny nose was experienced "about twice a month usually lasting no more than 
a day - unless I have a cold. Every few months, a runny nose will last about 2 - 3 days, 
but it does not feel like a cold". The severity of this symptom was rated 5. EOs "try to 
control it". This "takes longer" and the informant often needed to "apply a second dose 
after blowing her nose several times". EO "relieves congestion... or stops the production 
so it doesn't run". 
Sinus Headaches 
The informant treats sinus HAs in conjunction with sinus congestion "about twice 
a week" with a severity of 5.5. Undiluted EOs applied neat worked faster than tablet 
medications. "I don't take other meds, but I have when I need to. The oils work faster. 
Sometimes I need additional meds for control". During the past 3 months, she's taken 
antihistamines 2 - 3 times; guaifenesin 5 - 6 times. Antihistamine use would increase 
without EOs. 
Muscular Headaches 
Muscular HAs were reported 3 - 4 times weekly with a severity of 6.5. EOs were 
very effective in relieving this FM symptom with efficacy at 8.5 - 9. Basil and pepper-
mint were layered and applied neat; "rarely, lavender to relax". Symptom was relieved 
"within one minute". 
Neck Pain 
Neck pain occurred several times a week, usually in the afternoon or evening. 
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The frequency VAS, reported that this was "not severe pain generally", but the severity 
VAS rated this symptom as significant at 7.5. The informant had not differentiated be-
tween muscular HAs and neck pain radiating up to her head. During the past 3 weeks, 
undiluted basil, peppermint, and sometimes lavender EOs were used in a layering, neat 
technique. EOs were used "if it bothers me during the day time, like today" but "not used 
every night if I don't need it". Sometimes she massaged the occiput areas putting press-
ure on the FM points. 
The informant saw a chiropractor prior to the FM diagnosis for a work related fall 
with limited neck range of motion, back, spinal and neck adjustments. Back pain in-
creased with right hip pain radiation. The informant continued chiropractic treatment 
approximately every 3 weeks. 
Comments on the use of EOs were powerfully descriptive. 
If it doesn't work within a few times or days, why would you continue to use it? 
Try something else! Some medications take longer to get effects, like 
Meloxicam. The oils work faster. You don't have to wait. Sometimes, they 
don't work long enough, so I reapply if I have to. No harm. No foul, they're 
natural! Whatever works for me is what I'm going to do! That's my life and my 
pain. I'll treat it the way I want to, my way! 
Musculoskeletal Pain and Discomfort 
Generalized musculoskeletal (M/S) pain/discomfort was experienced daily, 80% 
of the time at a significant severity of 7 causing moderately severe discomfort. EOs 
made a moderate difference or improvement in the relief of this symptom. M/S 
symptoms challenged daily life and function. 
87 
It's all over, generalized. I have to put the oils all over. It's generalized, all over 
crap! They help, but they don't relieve the whole thing like they do in specific 
locations/areas. It's the nature of the beast! Generalized is harder to treat even 
with meloxicam. Then it's time to scale down, not vacuum, or garden. I have to 
scale back activities. 
Increased Sensitivity to Touch 
Increased sensitivity to touch on FM points at knees and sides of both legs were 
experienced "sometimes in certain places" at a minimal severity. "Maybe they don't 
bother me at the same time". Sandi used the diluted FM mix (Appendix I) in trans-
dermal applications. They are "moderately effective, not earth shaking in changes". 
Shoulder and/or Upper Back Pain/Discomfort 
Shoulder and/or upper back pain/discomfort were experienced 80% of the time on 
a daily basis with an increasingly moderate discomfort in severity. EOs made more than 
a significant plus difference or improvement. Shoulder FM points were more 
problematic involving arms rather than legs. "As a teacher, I'm writing more, canying 
books, grading papers; using arm muscles more". Undiluted neat EOs were used in a 
layering technique "same as the neck"; basil first, peppermint second and lavender as 
needed for the third step. 
Knee Pain 
Knee pain occuned a few times a month; experienced as a moderate discomfort. 




Heel pain was experienced at the bottom of her left (L) foot in the morning with 
generalized achiness a few times a month on a minimal severity scale. Using 
nonspecified diluted EOs, the informant did not notice much of a difference. 
Sleeping Problems 
The informant reported sleeping problems 100% of the time on a daily basis with 
a severity of 5; moderate discomfort. The informant was more comfortable falling asleep 
in the recliner, but had problems sleeping in her bed; "just too tired to sleep". Prior to 
FM, she slept on her stomach or sides, but now has to sleep with 2 pillows on her back 
from gastric esophageal reflux. Sleep improved after a hot bath with epsom salt and Skin 
So Soft™ . Undiluted neat layers of EOs were used transdermally, basil first followed by 
peppermint. These 2 EOs were used to treat pain that might keep her awake. A final 
layer of undiluted lavender EO was used neat to "relax". The informant did not rate the 
efficacy of this EO intervention during the data collection. Field notes (3/9/11) reported 
that the researcher phoned the informant to clarify the EO's efficacy on sleeping 
problems. The informant rated efficacy at an 8 providing a significant plus difference of 
improvement. 
Symptoms Not Routinely Treated with Essential Oils 
The informant did not have knowledge of all symptoms associated with FM. 
Trouble concentrating (thinking) "it was just me". Since jaw pain was rare, she never 
tried to treat the symptom. Exposures to cold made the informant "feel stiffer, contract 
more, and feel more tension in the neck/muscles and body". 
Sandi thought she was having cardiac problems, but not that FM could manifest 
as chest discomfort or heaviness. "Felt heaviness, feels like it skips a beat with shortness 
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of breath more at hours of sleep while trying to lie down and relax". She stated this was 
more of a recent happening since her last rheumatologist visit. Informant was refened to 
her GP for follow up on this symptom. 
EOs were rarely used for lower back pain (LBP). Field notes (3/12/11) 
commented that Sandi had difficulty reaching her mid/low back to apply EOs. On the 
EO Efficacy VAS, she usually did not have LBP, but results from the Frequency VAS 
reported that the symptom occuned 4 to 5 times a week; experienced about 30 % of the 
time on those days. Often out of alignment, the informant "hurt to walk". The Severity 
VAS indicated that LBP was significant at 7 causing moderately severe discomfort. 
Sometimes she woke up with LBP. 
The informant's hip pain was experienced about 4 times a week; usually 60% to 
70% of the time on those days. This pain was severe/consistent discomfort. Sandi first 
used basil on 2/25/11 for this symptom reporting minimal relief. Peppermint was not 
added for pain management since she did not associate this symptom with her FM. 
Sandi felt her inegular bowel problems were related to the prolonged use (2006-
2011) of meloxicam (Mobic™) prescribed by her rheumatologist to treat FM. She knew 
it was a nonsteroidal anti-inflammatory medication (NSAID) that "affects the stomach". 
Sandi did not know that anxiety was commonly associated with FM, or that you 
could feel overwhelmed by FM symptoms. She had feelings of anxiety 2 to 3 times a 
week; over-whelming feelings related to her FM symptoms occuned 5 to 6 times a 
month. These feelings of anxiety were bothersome. Feeling overwhelmed by these 
symptoms was scored slightly lower than anxiety at 3.5 or slightly more than a minimal 
experience. The informant had not used EOs purposively for these symptoms. 
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Feelings of sadness related to FM were experienced "maybe once a month" as a 
very mimmal experience. Although Sandi did not identify any frequency for suffering 
from her FM symptoms, she rated the severity equal to her feelings of sadness. The 
informant had not purposively used EOs for these symptoms. 
Living with FM resulted in 100% daily frustration producing a moderately severe 
discomfort, yet the informant did not know that others with FM experienced this as well. 
The informant became "frustrated when it impacts what I want to do in life". The 
informant had not purposively used EOs for these symptoms. 
The informant "sometimes" became angry because of living with FM. Anger was 
rated as 5.5 or a moderate discomfort. 
The oils treat my pain which keeps me from doing what I want to do. Oils help 
alleviate my pain so I can do what I want to do, when I want to do it. If I can live 
my life the way I want, I'm not as frustrated and angry. I'm trying to control the 
pain so I can do what I want in life. Sometimes, I can't control it all, so I get 
frustrated, "like I can't go on the gondolas in Italy. 
Visual Analog Scale Summary 
The 4 VAS tools were completed per research protocol using 29 symptoms for 
comparison of frequency, severity, and EO efficacy as a SC intervention. Over 34% 
(34.5%) of the FM symptoms were experienced daily; 80% of the daily symptoms were 
reported at significant frequencies; experienced 70% to 100% of the time. Twenty point 
7 percent of daily symptoms resulted in moderately severe discomfort to severe, consis-
tent discomfort. Forty-two point 9 percent of the severe symptoms (generalized M/S 
pain/discomfort, inegular bowel patterns; feeling frustrated because of living with FM) 
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were experienced daily for 80% of the time. 
EOs were routinely used by the informant to treat 12 (41.4%) symptoms. 
Efficacy ranged from 2 to 9. The average efficacy score was 6.04 indicating that most 
EOs produced a moderate plus difference/improvement in FM symptom relief. 
Information was compiled utilizing both diluted and undiluted EOs. 
The following table represents FM symptoms in frequency, severity, and the efficacy of 
EOs. 
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Cold Makes Pain Worse 
Body Feels Stiff 
Morning Fatigue 
Generalized Fatigue 
t Sensitivity to Touch 
Shoulder and/or Upper Back 
Pain/Discomfort 
Chest Pain/Discomfort 




Inegular Bowel Problems 
Problems Sleeping 
Anxiety R/T Symptoms or 
Diagnosis 
Overwhelmed by Symptoms 
Sadness Living with FM 
Suffered from FM 
Symptoms 
Frustrated Living with FM 
Angry Living with FM 





0, Dry eyes x 3 yrs 
2 x/week 
3-4 x/week 
Few times a week 
Once q other month 
Several times a week 
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N/A = Sandi did not acknowledge these symptoms within FM symptom clusters. 
*N/A = used once with result of 3 
93 
Per the informant's nanative comments and researcher's field notes, pre-mixed, 
diluted EOs were used during work hours to minimize attention and reactions by others in 
close proximity. Mixed, diluted EOs were chosen to globally treat all FM symptoms 
rather than carrying multiple, individual EO bottles for each symptom. Applied trans-
dermally in the school setting as needed. They were effective if the informant "catches 
and treats the symptoms early". Applications repeated every 5 to 10 min until desired 
effects were achieved. Diluted, mixed batches of EOs "help me get through the day". 
Undiluted EOs applied transdermally (neat) were effective within one to 2 min. 
EOs were more effective in the relief of localized versus systemic pain. 
EOs were helpful in establishing a healthier sleep pattern by blocking FM pain. 
Neat, undiluted, transdermal EO applications of basil were followed by peppermint. 
Sleep was also aided by an undiluted neat layer of lavender to enhance relaxation. 
EOs onset of action was faster in FM SC symptom management than oral medication. 
Sandi's SC philosophy reflected ownership. FM was "her" disease affecting 
"her" life. Consequently, treatment options were "her" choice. Sometimes, symptoms 
were not controlled. Pain and stress kept Sandi from doing what she wanted to do. 
Essential oils were used effectively to allow "her" life to continue via "her" choices. EOs 
helped alleviate pain, respiratory symptoms, and sleeping problems. Lavender EO helped 
her "relax". Sandi felt that using EOs minimized her frustration and anger to live "her" 
life the way she wanted. 
Rheumatologic Medical Records 
Eleven rheumatology visits were analyzed. Three visits, including the initial visit 
and FM diagnosis, occuned in 2006 (2 in October; one late December). Four medical 
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visits were analyzed in 2007 (February, July, September, and October). One visit was in 
August of 2008; one visit in February of 2009 and two in 2010 (April and November). 
Data were analyzed to increase understanding of FM symptom clusters, major/continuing 
patient complaints and medical recommendations/treatments. A thorough history and 
physical was reviewed to establish the FM diagnosis of exclusion and baseline status of 
the informant. 
Fibromyalgia Diagnosis 
Sandi was refened to the rheumatologist by her general practitioner (GP) for 
an evaluation of abnormal labs including a positive (+) antinuclear antibody (ANA) with 
continued muscle and joint pain. The first visit was on 10/16/2006. Diffuse arthralgias, 
episodic swelling, increasing soreness, erythema and warmth unassociated with move-
ment presented over a 5 month duration. Positive diffuse myalgias of the L perishoulder 
with pain including the forearm developed. Positive symptoms included: fatigue, LBP 
(especially lumbar), sleep disturbances (wakes up early); HAs (+ tension, negative (-) 
migraines, - scotomas, - aura, - nausea/vomiting (N/V). Negative symptoms included: 
snoring, apnea, fever, chills, nausea, weight loss, sickle cell anemia symptoms [shortness 
of breath, dizziness, jaundice] oral ulcers, malar rash, abdominal pain, bright red blood 
per rectum, melena, dysuria, hematuria, or Raynaud's. Complaints of + constipation with 
alternating loose watery stools wo recent travel were noted. Difficulty was reported get-
ting up from a kneeling position. There was no specific triggering event. A trial of 
sulindac (Clinoril™) was helpful with initial symptoms, but resulted in diarrhea. 
Family history was + for rheumatologic and celiac disease, - rheumatic arthritis 
(RA) or systemic lupus erythematosus (SLE); + history of juvenile rheumatic fever. 
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Sandi had no known drug allergies (NKDA). She was a nonsmoker with + alcohol use 
and did not exercise regularly. 
Current medications were noted as Allegra-D 60-120 mg extended release (ER) 
one tablet (tab) every (q) 12 hours (hrs) PRN allergic symptoms orally (PO), and 
carisoprodol (Soma™) 350 mg one tab at hrs of sleep (HS) PO. 
Review of systems included vital signs (VS): 122/80 millimeters of mercury, 74 
heart rate (HR), 14 respiratory rate (RR), 97.5° temperature, 170 pounds (#). The M/S 
system revealed back pain/stiffness, calf muscle cramps, localized pain, swelling, & 
stiffness to > 1 joint; + generalized muscle aches. 
The physical exam showed + bouchard's/herbeden's node, + L radial volar aspect 
ganglion cyst; + FM trigger points: occipitus, trapezius, gluteal, knee and greater trochan-
teri. Negative symptoms included synovitis, spinous process/perivertebral tenderness to 
palpation, crepitus, enthesopathy/dactylitis, rash, periungal erythema, sclerodactyl/ 
calcinosis/splinter hemonhage/subcutaneous nodules; axillary/cervical lymphadenopathy. 
Neurologically, the patient had 5/5 motor throughout, deep tendon reflexes 2+ 
symmetrically, sensation to light touch was intact. She had negative straight leg raises, 
tineal & phalen tests. Psychologically, the patient's affect was appropriate and normal 
(nml). She was alert and oriented times 3. 
The rheumatologist's assessment included osteoarthritis (OA) of multiple joints, 
ganglion of the L hand, myalgia, myositis, fatigue and FM. Plans included comprehen-
sive lab work-ups to rule out other diagnoses; Mobic™ (meloxicam) 7.5 mg daily PO as 
a trial Elavil™ (amytriptyline) 10 mg PO q HS to enhance delta wave sleep; hold 
sulindac and carisoprodol; consider proton pump inhibitors (PPIs) or histamine 2 (H2) 
blockers for gastrointestinal (GI) signs and symptoms (S & S) on Mobic™, calcium 1500 
mg daily PO; Vitamin D 400 IU daily PO; gentle aerobic exercise. A repeated ANA was 
planned at 4 months. All other labs were within normal limit (wnl) including Hepatitis 
A, B, C, magnesium, phosphorus, complete metabolic panel (CMP), and SLE; work-up; 
Vitamin D level was 31. 
On October 30,2006, trigger points included + elbow, neck, trapezius, gluteal, 
knee, and greater trochanteric. Bilateral lower extremity (BLE) knee pain was associated 
when arising from the chair with + knee crepitus. There was improvement in the sleep 
disturbance; - HA or weight (WT) gain. Vital signs were stable (VSS). Assessment 
included vitamin D deficiency, OA of multiple sites, FM, diffuse body aches, and sleep 
disturbance. After an extensive work-up (w/u), arthralgias were most compatible with 
(c/w) FM and - for chronic viral infection, immune rheumatologic or celiac disease. 
Per rheumatologist, FM required a multidisciplinary approach; the goal was 
therapeutic care. Recommendations included combining pharmacology treatments for 
pain, depression, and sleep disturbances with nonpharmacologic approaches including 
graded aerobic exercise, and the "promotion of self-efficacy for control of pain through 
self-management"; education on the importance of removing life stressors that could 
clearly exacerbate or precipitate a flare in symptoms. 
Mobic™ 7.5 mg daily PO and Elavil™ 10 mg po q hs were helping with symp-
tom management. Mild vitamin D deficiency was likely secondary to decreased sun ex-
posure so calcium 1200 mg and vitamin D 400 IU daily were prescribed. Gentle aerobic 
exercise was recommended with removal of stressful events. Education regarding trigger 
point injections was also given as a treatment option. 
Medical Progression 
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Active problems were identified as FM, fatigue, ganglion of the hand; myalgias, 
myositis, OA in multiple sites with degenerative joint disease (DJD), and vitamin D de-
ficiency. The hand ganglion never received treatment; was not involved in the FM 
symptom clusters. A hysterectomy for bleeding fibroids was noted in December 2006 
leading to a brief interruption in the use of Mobic™. Most lab results were consistently 
wnl. Weight and VS were considered. Vitamin D deficiency was continually addressed 
at each medical visit. 
Stress 
Throughout the MR, the rheumatologist continued to educate on the importance 
of stress alleviation. Stressors in the informant's life included her chronically stressful, 
but stable faculty position, home renovations, and incidents involved with her aging 
mother living nearby. Sometimes, tension HAs were documented. On the 11/02/2010 
medical progress note, the rheumatologist documented that "she is clearly aware of what 
causes her to flare which is really stress and not getting enough rest". 
Vitamin D Deficiency 
Vitamin D deficiency was related to insufficient sun exposure. Vitamin D ranges 
continued to fluctuate during 2006 to 2010; reported at 21.4-34 nanograms (NG)/mL. 
Normal ranges for vitamin D levels were established at > 30 NG/mL). The rheumatolo-
gist continued to adjust vitamin D doses in response to these fluctuating lab results. 
Musculoskeletal Symptoms 
Musculoskeletal assessments mentioned joint aches in the knees and neck toward 
the end of the work day on Mobic™ 7.5 mg PO daily. On 12/27/2006, the dose was 
increased to 15 mg PO daily, remaining the consistent dose. Tylenol™ was used 
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sparingly with improvement. Pain continued at the end of the day despite the increased 
dose of Mobic™. Ultram was considered PRN further analgesia (02/06/2007); ordered 
(7/2/2007) as hydrocodone-acetaminophen 7.5/750 mg, quantity 60 wo refills to take 1 
tab q 6 hrs PRN pain). Most recent progress notes documented that the rheumatologist 
did not want to initiate Cymbalta™, Lyrica™, or Savella™. 
Erythrocyte sedimentation rates were intermittently elevated with reported lab 
values initially at 39 mm/hr to 14 mm/hr on 04/15/2010. C reactive protein was elevated 
mildly on 04/15/10 at .08 mg/dL; reported as .52 mg/dL on 11/02/2010 indicating the 
highest level of risk for future cardiovascular events. The plan was to return to clinic in 9 
months. 
Positive trigger points were noted at the right (R) cervical neck muscles, 
occipitus, trapezius, elbow, gluteal, greater trochanteric, and knee. Bicipital tendonitis 
with extensive synovial/bursal inflammation, + R subarachnoid/subachromial bursitis; + 
pericervical/shoulder muscle tightness was also documented on multiple visits. There 
was intermittent knee crepitus wo significant knee effusion. Once, the R cervical trigger 
point was injected with 1 mL NS and 2 mL of 2% lidocaine with epinephrine which was 
well tolerated, but subsequently refused as a treatment option. A chiropractic order, 
02/24/2009, was noted for R bicipital tendonitis with ultrasound, deep tissue massage, 
electrical stimulation, stretching, an ergonomics evaluation and ice. 
Fatigue levels fluctuated as well as responses to diffuse arthralgias. ADLs were 
not interrupted from 2006-2010. Interference in I ADL was noted in the MR as 
discomforts associated with gardening and driving. 
Sleep Disorder 
Amitnptyhne (Elavil™) remained effective for HS sleep disturbance until discon-
tinued on 09/05/2007. Flexeril™ 10 mg PO q HS was trialed, tolerated with improved 
fatigue, but discontinued without further explanation per MR. 
Gastrointestinal Symptoms 
Gastrointestinal (GI) symptoms were noted on the initial visit. Further GI symp-
toms (9/5/2007) were noted as + burning sensation, + bloating, gassy sensation symptoms 
epigastric in origin worse in the supine position; improved with Prevacid™. On 
04/15/2010, frequent burping was noted with + occunence at night, + association with 
acid foods; increased burping with increased stress. On 11/02/10, progress noted docu-
mented more reflux symptoms with HS eating or coffee. Turns™ were intermittently 
taken as a self-initiated intervention. Prevacid™ samples were given for PRN use. Most 
recent recommendations were for an esophogastroduodenoscopy (EGD) and colonoscopy 
to rule out chronic gastritis since Mobic™ was taken since 2006. Colonoscopy and EGD 
were completed on 03/31/11. Per oral report, gastric reflux was from a weakened 
muscle, no gastric erosion or damage was noted. Recommendations included PPI or H2 
blockers. 
Complementary Therapies 
Medical records did not indicate all of the OTC vitamins that were taken in addi-
tion to vitamin D. Records indicated that refenals were made to acupuncture research; to 
add acai berry supplementation. Chiropractic interventions were previously noted. In the 
final progress note (11/02/10), the following statements were written:"Of note, she is also 
on these essential oils that she is putting on topically which has helped her fibromyalgia a 
lot.. .she is basically going to continue this as it is helping a lot". 
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Medical Record Summary 
The 56 year old female informant had a history of juvenile rheumatoid arthritis 
(JRA) with many symptoms of OA with DJD. Medical diagnosis affirmed literature 
findings that FM was a diagnosis of exclusion. The informant's lab diagnostics identified 
a vitamin D deficiency, and intermittent inflammatory indicators. She continued to live 
with symptom clusters of arthralgias, myalgias, myositis, and exacerbations of bicipital 
tendonitis treated (stable) on Mobic™ 15 mg PO daily. 
Consistent with literature, FM was a diagnosis of exclusion and responded to a 
multimodal approach. Sandi was educated and empowered to control FM symptoms by 
trying self-care modalities. Approaches included Mobic™ (meloxicam), a NSAID for 
COX-2 inhibition and a course of Elavil™ (amitryptaline) for sleep. The trusted rheuma-
tologist was supportive of CAM allowing options of SCM with chiropractic interven-
tions, acupuncture research study participation, and support for the use/research of EOs. 
The MR confirmed that faculty work was a constant, stable stressor at each office 
visit along with sleep deficit. The informant knew that lack of sleep and stress were 
triggers to FM flares. A mutually agreed upon stress management plan was absent from 
the medical plan, yet key to the control of FM flares. 
Indepth Informant Interview 
The indepth interview occuned on February 27,2011 at the informant's residence 
and lasted one hr and 50 minutes. The interview followed the informant's lived 
experience with FM through the initial diagnosis through her cunent lived experience. 
Information gained was grouped into the inception of self-care practice, midpoint self-
care practice, and the cunently lived self-care experience. 
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Inception of Self Care Experience 
The inception of the SC experience captured the beginning journey nanates stage 
one, or the "investigative and decision-making phase of self-care" (Orem, 1985, p. 123). 
Sandi reflected on self-knowledge and emerging information about FM. Effective SC 
required self-knowledge and information about environmental conditions. The informant 
continued to learn about FM. Sandi initiated multimodal self-care management programs 
hinged on the quest of knowledge and the rheumatologist's support of this integrative 
treatment approach. 
Past Medical History 
The informant discussed JRA in the fifth grade with a reoccunence in the eighth. 
She had gone to a rheumatologist "about 35 years ago" with joint problems. The 
informant was unaware that the current rheumatologist had diagnosed her with OA. 
FM Diagnosis 
Sandi sought medical evaluation from her GP in 2006 for the onset of L shoulder 
pain radiating to the elbow. She was unable to lift her arm without "excruciating pain". 
Her knee was also sore. Sandi suspected arthritis; "she was just getting older". Teaching 
the fall semester made her "tired"; "it's exhausting". She knew something wrong but was 
"not one to go running to the doctor for every little thing". 
Sandi described the FM testing and symptom questioning by a GP. Refenal to a 
rheumatologist was based on initial lab results and medical presentation. Sandi made an 
appointment; more blood was drawn. The rheumatologist tried to "eliminate the 
possibilities of what it could be by running tests that would be definitive". As a 
mathematician, Sandi understood this as a way to diagnose. "It made sense"; was not 
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upsetting. After lab work ruled out many possibilities, the rheumatologist "felt the 
different areas". "There's 18 points on your body and if 11 or 12 of those are tender to 
touch, that is an indicator of FM". 
Once the diagnosis was made, the informant focused on control. "I didn't know 
much about FM at the time, so that became a learning thing for me". She wanted to 
know what FM was and what to do about it. After the rheumatologist's explanation, "I 
knew it was a chronic condition; that it wasn't going away". Sandi stated that she didn't 
feel too badly with the FM label. "If we know what it is, we can deal with it; maybe try 
to control it". The doctor gave pain medication for her arm that was already feeling 
better. "Okay, at least I don't have that excruciating pain in my arm; I can live and deal 
with life". 
Trust in the rheumatologist seemed pivotal "from day one". "I thought she was 
doing a great job". Characteristics that seemed to contribute to this trust formation were 
identified as youth; desire to help; "explained things well; took time with me; genuinely 
concerned; knew what she was talking about". 
The etiology of FM was unknown. They "don't know what caused it" but "usual-
ly something triggers it". Sandi denied major emotional triggers or anything other than 
additional stress of work construction with "cement dust floating around.. .everyone on 
edge and stressed". The Ebstein Ban Virus (EBV) was diagnosed over "25 years ago". 
Treatment 
Mobic ™ was trialed "to see how that would react". The rheumatologist told 
Sandi "to get good sleep, otherwise it's not going to get things under control". Not 
sleeping well "was causing part of the problem". Amitriptyline was prescribed at night 
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"so that I would sleep better. This was a mild antidepressant". The informant stated that 
she didn't "like to be on drugs...I don't think of myself as being a depressed person...so 
that bothered me more then Mobic™". The rheumatologist explained that it was just a 
"mild thing to help you sleep". The informant felt "okay, I'm not going crazy; I'm not 
going to get into depression". 
Sandi knew Mobic™ was a NSAID used "to control the inflammation involved 
with fibromyalgia". The initial dose was trialed at 7.5 mg taken once in the morning. "It 
was okay, but I was finding that by the early afternoon, I was hurting again". The 
rheumatologist instructed Sandi not to take aspirin that could cause "stomach problems", 
but to take Tylenol™. "I bought a big bottle of Tylenol™. "I didn't use it; still don't". 
During her next 2006 appointment, Mobic™ was increased to 15 mg "working 
fine and I haven't had as much trouble. I noticed more indigestion and bowel problems" 
after Mobic™ was increased, but "not right away". She needed to be very careful to take 
the medicine with food. 
The informant described an early SCMI after forgetting to take her Mobic™ one 
morning. A safety routine was established by pouring a glass of water; putting out her 
vitamins and medicine. "If that glass of water's still there, I haven't taken them". Sandi 
went home "and sure enough, there it was on the sink because I put it out in the 
morning". 
Blood work was drawn with "checks in" from the rheumatologist "to make sure 
everything's okay". The informant took supplemental vitamin D as directed by the 
rheumatologist. A low vitamin D level was a "contributing factor that she wanted to 
remedy"; important to immunity. 
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Complementary Alternative Medicine 
Sandi discussed that pharmacologic interventions were not all that the 
rheumatologist had prescribed, but "that's what she had control over". Explanations were 
given about relief through acupuncture; chiropractors. FM was a learning process. "She 
made me feel like part of the solution" by saying "if you find something that works, let us 
know because we're still trying to get a handle on it. They're just starting to do research 
on this". Sandi participated in a FM acupuncture trial though not enthralled with 
treatments. 
Well, I went, I got the needles put in me, sat there for a while with the needles and 
soothing music.. .it was kind of relaxing. The needles, every once in awhile, kind 
of hurt (laughed). I'm not sure to what extent they helped. I'm not sure that 
really did a lot. 
Later, she felt regret. "I'm ashamed to say that I didn't follow through on the reporting 
months after it was over". She contributed this to "filling out forms and sending them 
back". Retrospectively, she realized they were trying to determine long term 
interventional effects. "I don't know which one (group) I was in". Treatments were "a 
week or 2" for "6 to 8 treatments". 
The informant's philosophy of SC outcomes described individual variance. "I 
believe that some things help some people, and some things don't help people. I think 
everybody's body is different; how they react is probably different to different things". 
Initial use of EOs occuned in spring of 2007. Sandi's sister was "into healing 
touch. I was extremely sore that night and she had some EOs with her". The sister "put 
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on some EOs and did healing touch at the same time". This "seemed to relieve some of 
the pain. I still was hurting, but it was better". 
Sandi talked to her cousin on the East coast who was "excited to learn that I was 
trying some". She felt strongly that EOs were important; "staying away from medicine 
and using natural things". 
Based on these experiences, EOs were trialed for relief of FM pain. EOs were ob-
tained through her sister. "She mixed up a few of them for me and showed me how to 
use them; when to use them". Sandi said she "pretty much" followed instructions. 
Initially, EOs were not used daily, but "when I felt I needed a little bit more than what my 
medicine was giving me. They helped; made it a little better. I don't know that they 
miraculously took everything". 
Self Care Practice: Midpoint 
Sandi's choice at the closure of phase one was to continue a multimodal treatment 
approach to FM, including the use of EOs. This set the goals for stage two or the 
"production phase of self-care" (Orem, 1985, p. 123). This second phase concentrated on 
operations that occuned after the SC decision allowing engagement in a selected course 
of SC action. Focus on how and why EOs were continued and integrated into the infor-
mant's lifestyle unfolded. Sandi discussed the effects on functioning, medical treatment 
regimens and EOs' effects. Nanatives noted changes in SC practices involved with EOs; 
her overall well-being. Orem's action phase began with the decision to meet FM SC 
requisites and demands. Sandi's plan was to "control" the FM symptoms to maintain her 
faculty position and enjoy her lifestyle. Sandi's SC plans required an expenditure of her 
depleting energy to satisfy demands for FM care. Sustainable effort was deliberate to 
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achieve specific, favorably perceived outcomes. The attention was on performed actions, 
and evidence to judge these actions. 
Quality of Life 
Sandi tried to convey feelings on how this life long chronic disease impacted her 
quality of life (QOL). "I was not as energetic". She didn't want to say "depressed, but it 
was getting me down that I had to deal with this and that, I wasn't feeling 100%" or 
"bumming me out a bit". She followed statements quickly with how she accepted the FM 
diagnosis; tried to control consequences. "I continued my life. I did what I could. I 
mean you live with these things". She felt signs of improvement by "sleeping 
better.. .and getting more rest". 
Treatment 
Sandi continued Mobic™ 15 mg; doses of vitamin D. Her rheumatologist 
continued to monitor lab results to maintain safety. "For some reason, I don't absorb 
vitamin D". She also continued to use large amounts of supplemental vitamins in 
addition to vitamin D. Sandi continued to see a chiropractor. This helped to keep her 
body in alignment. 
Now, Sandi became aware of sinus problems. It "seems like I've had nasal 
problems for a long time" before FM, but "since my FM, constantly. I hardly ever feel 
that I can take a big, deep breath through my nose and get my lungs full". She feels that 
this is a reason she doesn't sleep well. 
Complementary Alternative Medicine 
The informant could not recall when she informed the rheumatologist of her EO 
use. "Some days were worse than others". Tylenol™ was taken "in the afternoon or 
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evening... if I was hurting more". The rheumatologist asked which EOs were used. The 
informant asked if there were any contraindications. The rheumatologist answered "no"; 
asked if they were helping. Sandi responded "I think so". 
Sandi "wasn't completely sold on it (EOs) at first. I don't know if it takes a while 
to get into your system and start to keep things under control, but it seemed not to hurt. It 
seemed to gradually get better as I used it... what's the harm"? The informant felt better 
"knowing it was something natural; that I didn't have to bump up a medicine dose of 
drugs". Choice of treatment was important. Others with FM were taking Lyrica™. 
Sandi was fearful of this new drug that was initiated by television advertisements 
detailing side effects and risks associated with use. 
I think the EOs added that little extra I probably needed rather than to up the dose 
again and/or switch medicines. So, I felt that was a good alternative. I could use 
it when I needed it, not that I had to have it all the time. 
Sandi did not use as much EO "as I'm using now; probably used it more on my 
arms and legs. I don't remember using it on my neck or shoulders, because at that point, 
I didn't think that was a problem. I thought that whatever I felt was from stress, not from 
FM. So I didn't think to put it there. I didn't use it every day". 
The informant controlled the actual implementation of EOs as a SCMI, 
transdermal application, dose, and frequency. She knew these flammable oils should be 
protected from sunlight; not ingested and to avoid eye contact. 
108 
It was nice to have the control.. .not worry about using too much or too little, or if 
it was going to be a problem. I figure as long as it helps and I feel better, I'm not 
going to worry about it. Why should I? 
The informant developed a nightly SC pattern using EOs to get better sleep. 
Sandi's sister mixed diluted respiratory EOs. "That worked; it helped. I would put some 
on before bed. It would help me breathe a little better. I could sleep a little better then if 
I didn't take them. So I continued those". 
The informant stated her sister helped decide what to put into mixes and how 
strong to make them. She "talked to me about what seemed to work; what I felt I needed 
more for the FM". Sandi purchased bottles of EOs to keep on her bedroom dresser. She 
started mixing SC oils under her sister's guidance: one for respiratory symptoms; one for 
FM pain and muscle symptoms. Diluents were 100% olive oil. Dilutions were titrated 
with different EOs meeting the informant's fluctuating needs for symptom management. 
Currently Lived Self-Care Experience 
The enduring nature of FM's chronic conditions mandated self-management inter-
ventions (SMIs) as an imperative, inevitable, and non-optional behavior (Bodenheimer, et 
al, 2002; Cross, 2007). Sandi and her rheumatologist used SMIs to create processes and 
opportunities to increase treatment involvement; bring control and order back into her life 
(Kralick, et al., 2004; Newman, et al., 2004). Care strategy nanatives reflected protracted 
time frames; clarified patient roles and acceptance of responsibilities (Newman, et al.; 
WHO, 2002). 
The FM illness experience was not manageable through a disease focus. 
Chronicity mandated heterogenic adaptation wdthin the reality context of Sandi's lived 
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experienced. Therefore, a variety of techniques managed symptoms and maintained 
social role normalcy (Larsen, 2009). Self-control opportunities or SM emerged as out-
comes of uniquely perceived and processed stressors within the lived context (Delmar, et 
al., 2006). At the conclusion of the interview, it seemed clear that interventions promot-
ing patient roles in the management of chronic conditions resulted in improved outcomes 
(WHO, 2002). For Sandi, participation in decision-making and treatment planning in-
creased efficacy and efficiency (Holman & Lorig, 2000). She chose actions that 
improved her health. Sandi's knowledge, motivation and skills to cope with the lived 
experience of FM encompassed self-monitoring, effective cognitive, behavioral and 
emotional responses to maintain QOL (Barlow, et al., 2002). 
Treatment 
Sandi continued to follow FM care recommendations of her trusted 
rheumatologist taking Mobic™ at 15 mg daily with increasing GI complaints of lower 
abdominal cramps, frequent morning stools, looser in consistency, "a little mucous" with 
bleeding, and hemor-rhoids that increased her discomfort. She modified coffee intake, 
diet choices, and eating patterns. Sandi "self-medicated" using OTC products like 
Neosporin Ointment™ and hydrocortisone. "I read more labels these days". She takes 
a long list of vitamin supple-ments including titrated vitamin D doses. Lab work 
remained wnl ensuring patient safety. 
The rheumatologist gave Sandi samples of Prevacid™, but she did not really want 
to take more drugs for prolonged periods of time. The rheumatologist told Sandi to just 
take it when she needed it. "So then I did use it one day.. .and it did help. I still have that 
option available". The informant knew not to eat 3 to 4 hrs before HS, yet she liked 
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bedtime snacks. 
Complementary Alternative Medicine 
The chiropractor also believed "in managing pain without drugs. He would rather 
put me back in alignment, and that has helped". Sandi did not know if the neck pain was 
from FM or misalignment. Chiropractic treatments kept skeletal alignment. "The 
chiropractor helps me when I'm hurting...and my hip is causing me to walk differently, 
putting more pressure on my other knee; I'm walking like an old lady". 
The EOs "sit on my dresser in my bedroom". They are quickly accessible. Oils 
are all labeled and "kept in the same position" since she can't read them without her 
glasses. 
Sandi takes a mix of diluted respiratory EOs to work "because I'm not going to 
bring several different bottles.. .this is more convenient". The informant feels a mix of 
diluted EOs aren't "as obvious to people; I don't bother people" yet "it helps me enough 
to get me through". The informant adjusts EOs into a SCMI. "I fit it into my 
routine...at work. I put it on more often than if I was at home using undiluted EOs. 
Undiluted would hit more; work faster, quicker". 
In the future, Sandi would mix EOs to bring to school under her sister's guidance. 
"I may not dilute them as much". Jojoba wax would be the diluent rather than olive oil. 
At night, the informant applied EOs undiluted, neat and layered. This was the 
most recent change in her SCMI technique. "It works more effectively; quicker. I feel it 
makes a difference faster". 
The informant discussed an example of her sister's communication and resource 
guidance in the quest for FM symptom management. "I hadn't been using basil. I was 
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using a tansy blue which was supposed to be an anti-inflammatory". The cunent mixture 
was not effective. Sandi's sister said "well, maybe we need to try this, and why don't 
you try that"? 
One night while talking to her sister, she had neck pain that "was going into a HA. 
I was hurting". The sister said "why don't you go and put this on straight and see what it 
does"? She stayed on the phone while Sandi tried the intervention. The undiluted basil 
EO heated up.. .1 don't know if it relaxed the muscle.. .or what FM really involves. I do 
know that it's an inflammation of the CT that is muscle tendons, whatever connects 
everything. So maybe the heat from that loosened things up. I don't know how it 
stopped the pain, but it helped. Sandi described the layered neat, undiluted transdermal 
applications on dry skin that absorbs quickly "so they get in right away". She "put a 
drop or two of the basil first, then some peppermint, and probably some lavender. I 
didn't mix them together". Using a zero to 10 Likert scale for pain, she described her 
pre-intervention pain level as 7 (severe and significant) out of 10. Post-intervention, the 
informant rated her pain as a 1-2 (mild and insignificant). "I was hurting, uptight, and 
tense. So at least that helped me relax a little bit, I could unwind". The informant 
described her pain tolerance. "I can handle a lot of pain, but that helped; I didn't have to 
handle a great deal of pain after that. I put some more on before I went to bed that night, 
too". 
Sandi described several times when she woke up with a HA in the back of her 
neck. She took meloxicam. "That takes longer to work, but it helped. I think I put some 
oil on. I don't think I put very much on, though, because I didn't want to smell a whole 
lot when I went to work". EOs helped before the meloxicam, "but it [HAs] started my 
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day off badly". 
Nanatives supported the use of EOs to decrease or replace allopathic, 
pharmacological agents. Without the use of EOs, "I'd be taking more Sudafed™ and 
Benadryl™-type drugs to try and get it (sinus) under control". Sandi felt she might have 
also required a stronger drug then meloxicam with the "religious addition of 2-3 
Tylenol™ doses in the afternoon" for pain. 
Quality of Life 
Sandi did not feel that her FM was getting worse or progressing in severity, 
although "some days, it feels like it's gotten worse". She was grateful that she never felt 
that initial excruciating (10 out of 10) pain again. The informant described her FM pain 
as soreness, tiredness, an achy thing. When I feel worse, it's usually in my shoulders and 
neck; my arms feel weighty, heavy, tired, and sore. It feels like I have to just sit; do 
nothing because it bothers me to move and lift them to do anything. That's when it's the 
worst; I just sit and do nothing. I veg until I can get things under control again.. .with the 
oils. 
Function and Activities of Daily Living 
Sandi is a dedicated teacher. She does not call in sick. "It's more stressful for me 
to take a day off than to go into work and deal with it there". Sandi attributes this stress 
to the creation of detailed lesson plans, and substitute planning. Usually, FM does not 
bother her in the morning, but later in the day "because I'm tired; I've overdone 
something; I've worked too hard at something; I've dug in my garden too much, or I've 
vacuumed too long". Repetitive actions trigger it, but sometimes she needs to get things 
done. Knowing how to pace and what you can do is "all part of it". 
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Self-Care Philosophies, Perceptions and Accountability 
Sandi feels FM is "all learning. You make choices and live with those choices. 
They're my choices". Sandi's goal in using EOs is to help manage symptoms that could 
change her ability to function. 
Fear of an unknown chronic disease trajectory was discussed by the informant. 
"Things have evolved and they will probably continue to evolve. I don't know if this 
disease gets worse as time goes on. I have no clue; I don't know if anybody does". This 
scared Sandi. 
It's triggered me more into looking at long-term care (LTC).. .I'm going to be get-
ting that kind of insurance because I'm single. I have no offspring. I have no 
spouse. I have no one to really take care of me later if I need help and I'm not 
going to become a burden to people I love. If they want to help, that's fine. That 
way, if it gets to the point that I need help at home like vacuuming, cleaning, or if 
I can't take care of myself, what do they say, 2 out of 3 or 3 out of 5 daily life 
activities, I will have somebody come in and help me...decisions about my life 
and my future if things get worse...as you get older, your body changes. You 
can't do everything.. .so you deal with it. 
Sandi spends money for SC absorbing out-of- pocket medical deductions from the 
medical insurance provided by the school's district. Sandi co-pays for medication, LTC 
insurance, the chiropractor, and the EOs. Her financial planner advises her to teach 5 
more years before retiring at 62 years with her teacher's pension and paid home 
mortgage. Sandi feels confident that she can achieve this goal. 
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Indepth Interview Summary 
Sandi uses a multimodal approach to SCM. She chooses SCMIs to control FM 
symptoms. The chiropractor helps to keep Sandi's body alignment. Mobic™ 15 mg PO 
helps control generalized malaise, and achiness on an ongoing daily basis. "On another 
day if I'm hurting, I put the oils on my neck going up to my head; it keeps me from 
getting a massive HA". The informant concludes that "I guess you could say I weigh 
them equally, but on any particular day, one may be more important than another". The 
whole point of this is to allow her to be who she wants to be. "I'm not willing to get off 
the meloxicam, stop going to the chiropractor, or stop using the EOs". To Sandi, FM 
management is SCM. This includes the professionals she seeks to help her control this 
complex disease "which many do not understand". It involves making choices in 
activities, life styles, vitamins, medications and CAM treatments. Sandi tries to live 
through this, go to school each day, and continue her meaningful life. "This is my life. 
Teaching is my life...to help kids. I go to games, help at school, and do the yearbook. 
Sometimes, I don't get home until 6, 7, or 8 PM, long hours". 
The informant felt sorry for anyone diagnosed with FM. She hoped a good 
rheumatologist listened, cared for them, and gave them what they needed. "I would tell 
them how I was handling things" if they asked. The informant felt that FM was a journey 
"a personal thing". She would not impose her way of handling FM. Powerfully, Sandi 
shared her wisdom for future practitioners. 
How you treat this disease is a personal thing...everybody needs to treat it in a 
way that makes them feel comfortable. They need to make decisions for 
themselves. Nobody really understands it (FM) unless they have it themselves. 
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As a math teacher, I know there's no one way to solve a problem. There is no one 
way of handling something that is going to work for everybody... because of their 
personality, their life, or what they have to cope with. A health care provider can 
advise and suggest, but I think they need to give the patient enough respect and 
courtesy, to control their own situation. Respect any decision they make 
regarding their own life. It's the person's life and it's their decision. You don't 
do it if they don't consent to you doing it. Give them the facts, knowledge, and 
information. If they are able to make their own decisions, why should somebody 
else make their decision for them? As long as I can, I will manage this disease 
Essential Oil Data Analysis 
The informant's SMIs included the transdermal applications of tropical basil 
{Ocimum basilicum), peppermint {Mentha x piperita), tea tree {Melaleuca alternifolia), 
eucalyptus {Eucalyptus globulus), and lavender {Lavandula angustifolia). The informant 
also used EO diluted blends for FM and respiratory symptoms. Field notes and 
observations verify that all cunently used EOs, except the eucalyptus, were obtained 
from Kneading Wellness ®. The Delaware State University's Department of Agriculture 
and Natural Resources verified EO analysis in an independent lab by gas chromatography 
(GC). Analysis did not detect adulteration and were identified as: Basil EO-tropical 
Ocimum basilicum, a cultivated USA plant with methyl chavicol; Lavendev-Lavandula 
angustifolia, v. vera, wild, flower and plant from Bulgaria; Tea Tree-Melaleuca 
alternifolia, leaf and branch from Australia; Peppermint, Mentha x piperita a super plant 
from USA. Eucalyptus globulus did not have GC and was obtained over the internet. 
Essential Oil Literature Review 
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An indepth literature review was presented in chapter two. Research trials and 
results were presented in that section. 
Aromatherapy's early trials suggested that EO interventions helped patients 
manage pain, stress, and depression (American Cancer Society, 2008). Specific EOs 
supported dif-ferent body systems. EOs were rapidly absorbed through skin (Jager, 
Buchbauer, Jirovetz, & Fritzer, 1992) bringing 21% increased oxygen to cells within 20 
minutes of application (Smith, 2009). Transdermal, undiluted, neat EO applications 
were French aromatherapy techniques (EOPR, 2004). External, low dose use of EOs had 
very little evidence of likely interactions with drugs that are largely site and dose-
dependent (Hanis, 2008). 
Literature reported that basil, peppermint and lavender had antinociceptive 
properties. Basil inhibited anti-inflammatory cytokines. Peppermint relieved HAs with 
efficacy comparable to acetaminophen; calmed IBS; potentiated effects of other EOs. 
Lavender had anti-conflict and anesthetic properties with actions on GABA receptors 
comparable to benzodiazepines. Antimicrobial properties abound supported by bench 
science and laboratory testing. 
Essential oils can become an integral SC ritual to improve well-being (Smith, 
2009). Subjects perceive EOs differently leading to differential effects on behavioral 
measures (Ilmberger, Heuberger, Mahrhofer, Dessovic, Kowarik, & Buchbauer, 2001). 
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Chapter 5 Discussion 
Introduction 
This indepth, single case, embedded research design was analogous to a single 
experiment (Yin, 2009). The study represented an extreme, unique, revelatory case. The 
overall purpose of this evaluative, descriptive research was to explore proposed causal 
links in the self-care (SC) use of essential oils (EOs) over several years of use to mitigate 
chronic fibromyalgia (FM) symptoms within context reality. The study addressed 4 
questions related to how and why: (1) the informant used EOs in self-care; (2) 
multimodal approaches used to manage signs and symptoms (S & S) of FM; (3) EOs 
helped the informant maintain function and activities of daily living (ADLs); (4) the 
informant integrated self-care management (SCM) with EOs, their use, effects and 
outcome into the context of her daily life. 
Chapter 5 reviews embedded units of analysis including chronic FM symptoms, 
self-care deficit (SCD) using Orem's (1985) theoretical foundation; EOs. Internal 
validity looks at pattern matching within quantitative and qualitative data using principles 
of SC and integrative medicine (IM). External validity reviews study findings related to 
IM principles and SCD theory (Maizes, et al, 2009; Orem). Reliability addresses 
protocols, specific EO species, grades, and amounts used in SC. Finally, this chapter 
includes significance to nursing, recommendations, study limitations, and conclusions. 
Embedded Units of Analysis 
Three embedded units analyzed data in this single case study research design. 
Together, these comprehensive units helped construct the complex reality of the 
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informant, the lived experience of FM, and interventions comprising self-care 
management. 
Chronic Fibromyalgia Symptoms 
Fibromyalgia symptoms identified in literature reviews were integrated into 3 of 
the 4 VAS tools. A total of 29 symptoms were chosen to thoroughly cover FM's 
complexity. Items were repeated within the Chronic Symptom Frequency, Chronic 
Symptom Severity and EO Efficacy Scales. The outcomes of living with FM were 
measured within the Function and Activities of Daily Living Scale. 
The Chronic Symptom Frequency VAS clarified that only 10 (34.5%) of the 29 
FM symptoms were experienced daily. Eight (80%) of these 10 symptoms were rated as 
significantly frequent or 70% to 100% of the time. The other 2 daily symptoms or 20% 
were rated at minimal frequencies. The average score for daily symptoms was rated 
significant at 7.25. Approximately one third of the symptoms identified in the literature 
review were experienced by the informant and 80% of these symptoms were rated 
significantly frequent. 
The Chronic Symptom Severity VAS identified 6 (20.7%) severe symptoms out 
of 29 ranging from moderately severe discomfort (7 out of 10) to severe, consistent 
discomfort (9 out of 10). Most of the 29 symptoms were rated as bothersome (4 out of 
10) to more than increasingly moderate discomfort (6.5 out of 10). Mild severity 
accounted for 9 (31%) of the 29 symptoms with the absence of one symptom (teary eyes) 
to slightly more than minimal. 
The Function and Activities of Daily Living VAS consisted of 24 items. Two 
(8%) of the 24 behaviors severely and/or consistently interfered with function. These 
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behaviors included gardening, doing outside chores, and/or hobbies. Completing 
repetitive actions resulted in the worse imaginable interference. The majority of 
behaviors, 14 (58.3%) out of 24 resulted in a bothersome interference to an increasingly 
moderate interference. 
Instrumental activities of daily living (IADL) showed mild to severe (2-9 out of 
10) interference for 11 (46%) of 24 behaviors. Seven (29.2%) of 24 behaviors showed 
bothersome to the worse imaginable interference (4-10 out of 10). One third (8) of 24 
behaviors were rated as minimal to no interference. The average of 24 behaviors was 4.7 
or moderately severe interferences. Most of the interferences were noted in IADL 
activities versus ADLs. 
The MR conoborated symptoms noted in the VAS tools. Identified FM trigger 
points paralleled Sandi's symptom complaints on the VAS tools. Scope, severity, 
location of trigger points and pain seemed down played in the MR compared to VASs, 
and interview that harmonized symptom presentations. This discrepancy related to the 
informant's knowledge deficit of all FM symptoms, truth-telling by the informant during 
medical visits, and/or perceptual variances between the informant and the rheumatologist. 
The interview supported VAS and MR findings. Comments and observations on 
the VAS tools, field notes/observations, and indepth interview transcripts highlighted 
etiologies, trends, and challenges of daily life with FM. Narratives explored conse-
quences of FM symptoms, sometimes so severe the informant was unable to do anything 
at all. 
Self-Care Agency 
Motivation for SC agency was demonstrated by the informant from the onset of 
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diagnosis. Sandi's goal was to control the symptoms of FM. She took meloxicam daily, 
effective for generalized, systemic FM symptoms; created a morning ritual for safety 
administration. Acupuncture was trialed but discontinued after the informant failed to 
detect sustainable improvement. Sandi continued chiropractic treatments that had a 
baseline efficacy prior to the FM diagnosis. Finally, through the support of her family, 
Sandi ventured into the use of EOs, becoming more knowledgeable in applications, 
doses, mixtures and effects. The informant's decisions to follow SC actions were framed 
on successful outcomes achieved through newly acquired knowledge. 
Sandi discussed multimodal approaches to SC actions that became subsystems 
within her SCM program. Knowledge-seeking sequences involved the health care team: 
GP, rheumatologist, chiropractor, and a registered nurse (RN, her sister). Sandi was 
internally oriented to SC actions through her trusted rheumatologist and sister. She kept 
healthcare appointments, continued lab monitoring for safety and called appropriate 
healthcare provi-ders as needed. Sandi accepted accountability for how the FM 
symptoms affected her life. Choices made tried to control the symptoms that interfered 
with her life. 
The "investigative and decision-making phase of self-care" (Orem, 1985, p. 123) 
was completed during the inception of SC practice. Clearly, Sandi enunciated that the 
EOs worked, did not harm, and consequently were adapted into her SCM program. 
The "production phase of self-care" (Orem, 1985, p. 123) focused on operations 
occurring after the decision to use EOs. Plans of action changed from the inception of 
SC, when the sister was mixing, instructing, and prescribing the EOs. The interview 
identified 
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midpoint SC actions involving the informant's knowledge acquisition, attainment and 
self-mixing of EOs. Sandi's sister evolved into a resource consultant when mixtures 
where ineffective in symptom relief. Finally, within the cunently lived SC experience, 
Sandi experimented and adapted the use of undiluted, neat, layered transdermal 
applications of EOs because "they work faster". 
Self-care deficits were translated as knowledge deficits by the informant and 
health care team. The health care team continued to empower Sandi's knowledge 
acquisition. The goal was to control symptoms. Barriers included Sandi's difficulty 
applying EOs to painful back areas since she could not reach those areas because she 
lived alone. Sometimes there was nothing that she can do except "scale everything 
down" resulting in decreased instrumental activities of daily living (IADL). 
Self-care regulation is a human function. The informant meets Orem's (1985, p. 
99) 6 categories of health-deviation SC requisites. First, Sandi seeks and secures 
appropriate medical assistance to manage FM. Secondly, she is aware of and continues 
to learn about FM, its effects and results within her lived experience. She knows of her 
vitamin D deficiency, and monitors lab results in collaboration with the rheumatologist. 
Interview transcripts show a knowledge deficit of OA with DJD and how it complicates 
FM symptoms. Thirdly, Sandi follows medical advice trying CAM interventions and 
controlling FM symptom manifestations. The informant usually carries out prescribed 
medical regimens, but she stresses that choices are not the health care teams' but hers. 
The professionals are consultants, not decision makers. An example of this is 
endoscopy/colonoscopy medical requests from April, 2010 which were finally completed 
a year later. Fourth, Sandi is aware of positive and deleterious effects of chosen 
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treatment modalities. She speaks of meloxicam's GI effects, but feels the positive 
outcomes outweigh negative effects. Fourth, the informant recognizes that sleep deficit 
and stress flare FM symptoms, but chooses to make decisions on when these violations 
need to occur; accepting consequences of these behaviors. She does not have a stress 
reduction plan especially since FM impedes her hobbies. The fifth category of self-image 
acceptance within the limitations FM imposes is most difficult. Sandi "pushes herself 
when she feels better" acknowledging possible consequences she is willing to accept. 
Finally, she continues to learn how to live with FM making anangements for LTC 
insurance in the hope of "not burdening her family". 
Orem (1985, p. 100) reviews 6 operations to determine therapeutic SC demands. 
The first requires identification and particularization of existing, emerging, or projected 
developmental and health-deviation SC requisites. Sandi demonstrates this requirement 
through multimodal SC approaches to manage FM and future prediction for LTC deter-
mination needs. 
The second operation involves the identification of internal or external variables 
that affect the attainment of SC. Sandi knows that stress and sleep deficit flare FM 
symptoms. She chooses, however, lifestyles that facilitate these triggers, pushing limits 
and living life "my way". She accepts consequences of her action feeling this "comes 
with the territory". 
The third operation is the identification of intenelationships among various SC re-
quisites. Sandi clearly states when and why she uses her pharmacologic and CAM 
therapies. She notices that her FM symptoms become worse in the afternoon and 
evenings after she "works too hard" and completes "repetitive actions" especially with 
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her upper arms. 
The fourth operation determines how SC interventions affect other SC requisites. 
Sandi recognizes that if she uses EOs she requires less analgesics, antihistamines and 
decongestants. 
Finally, total SC actions are specified in duration and integration of elements 
within the context of daily living. Chiropractic appointments are set approximately every 
3 weeks. EOs are used nightly for the relief of nasal congestion and PRN for pain, stress 
reduction and sleep. 
Sandi's nanative conveys daily courage to live with chronic FM as a challenge 
with ramifications. Sandi initiates SC activities to manage and treat chronic conditions 
associated with psychosocial consequences and lifestyle changes. She demonstrates 
SCM adherence to treatment guidelines. Data analysis concurs that SCIs are non-
optional to manage FM. Sandi uses SMIs to create control processes over FM treatment 
and bring order back into her life. 
Essential Oils 
Essential oils were used by Sandi to control symptoms of HAs, neck and shoulder 
pain, respiratory symptoms and sleep disturbances. They worked faster than oral medica-
tions. She used them when she needed them; as she decided. She stored, diluted, 
inhaled, and transdermally layered EOs or used them undiluted and neat. Choices 
depended on her setting and/or the intensity of symptoms. Sandi felt it was great to get 
some control back. 
Initial EOs were obtained from Green Valley®. These were good medicinal 
grade EOs, but distributors did not complete gas chromatography. In 2009, EOs were 
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obtained from Kneading Wellness® with gas chromatography verification. 
Internal Validity 
Internal validity looks at pattern matching within quantitative and qualitative data 
and for this study, specifically, using the principles of SC and IM. Quantitative and 
qualitative data support patterns of SC and IM within this CSR. The MR documents the 
rheumatologist's approach to multimodal pharmacologic and nonpharmacologic 
interventions including complementary alternative medicine (CAM). The use of CAM is 
also woven throughout interview transcripts and the EO Efficacy Visual Analog Scale 
(VAS). Interview highlights show Sandi's choice to take meloxicam, creating a safety 
process around its administration. The MR confirms the use of this medication in stated 
interview dose. Both MR and interview transcripts verify chiropractic interventions 
successfully integrated into the SCM program. Patterns also match EO's use to manage 
FM symptoms noted in the MR, interview and EOs Efficacy VAS. 
Patient and healthcare team members were partners in the healing process. The 
rheumatologist and sister (RN) encouraged SC. Team members empowered Sandi's 
decisions to manage symptoms. Treatment decisions encompassed health, wellness, 
mind, body and disease needs. Both conventional and alternative methods facilitated her 
healing response. Effective, natural, less invasive interventions were used whenever 
possible. Data from the interview, EO Efficacy VAS, MR, and literature reviews docu-
mented effective natural interventions rather than increased pharmacological antihista-
mines, sleeping medications and/or decongestants. New paradigms of SC were accepted; 
EOs helped maintain overall health and manage FM symptoms as supported in the 
interview, MR and EO VAS documentation. 
Literature reviews and research on EOs represented a novice state of knowledge. 
Effects included, but were not limited to, sedation, anti-inflammatory, anti-anxiety, anti-
conflict, antidepressant, muscle relaxation, anti-allergenic, antimicrobial, anti-mutagenic 
properties. Also, EOs chosen by the informant supported her respiratory status and 
helped to address sleeping disturbances. Multimodal approaches to SC matched patterns 
within the interview, MR, and literature review. Sandi was empowered to bring control 
back into her life. 
External Validity 
This CSR supported the integration of Orem's (1985) SCD theory, principles of 
SC and IM. The informant evolved in SC patterns. After deciding to try EOs, Sandi 
learned to mix, dilute and apply these creating rituals to manage the symptoms of FM. 
Health care providers demonstrated the principles of IM by empowering the informant's 
SC, educating the patient, encouraging SC decisions and using natural choices (CAM) 
when available and effective. Self-care and SCD integration were previously addressed. 
This CSR encompassed the 9 principles of integrative medicine (Maizes, et al, 
2009). The healing process was collaborative between the informant and health care 
team, as supported by the MR and interview, to honor Sandi's uniqueness. Health, 
wellness, mind, body, and disease were considered as Sandi made her treatment choices. 
Sandi appropriately chose conventional and alternative methods that would facilitate her 
body's innate healing response. Interventions more natural and less invasive were the 
informant's preference. 
Good medicine was based in good science. The rheumatologist's FM diagnosis 
of exclusion and multimodal approach to care was supported in the literature review. 
Self-control opportunities or SMIs emerged as outcomes of uniquely perceived and 
processed stressors within Sandi's lived context. Self-care interventions promoted 
Sandi's role in the management of FM. She felt her response was better than many 
others with FM. Participation in EO decision-making (doses, concentrations; applica-
tions) and treatment-planning (undiluted use at home and diluted at school) increased SCI 
efficacy and efficiency. 
The use of self-care EOs in FM is a new paradigm; certainly further research is 
needed. Ultimately, Sandi clearly states how to proceed with treatment based on values, 
beliefs, and available evidence. Decisions are hers to make. Health care team members 
are consultants to those decisions. The informant's goals are to control FM as long as she 
can and to make choices to keep her healthy. 
Reliability 
The established CSR protocols followed the data collection as outlined in Chapter 
3. There were two exceptions. Per the informant's request, the researcher asked ques-
tions on the EO Efficacy VAS and recorded answers and comments. Secondly, the in-
depth interview occuned on the same weekend that the 4 VAS tools were completed 
instead of one week later per informant request. 
The principle, undiluted EOs that Sandi used for transdermal, neat application in-
cluded: Basil, Tropical (Ocimum basilicum) CT methyl chavicol, cultivated, Plant USA; 
newly added, Eucalyptus (Eucalyptus globulus); Lavender (Lavandula angustifolia), v. 
vera, wild, flower and plant, Bulgaria; Peppermint (Mentha xpiperita), super, plant, US; 
Tea Tree (Melaleuca alternifolia), leaf and branch, Australia. 
Specific amounts of EOs were modified and titrated by the informant as needed to 
manage FM symptoms. Most EOs (except Eucalyptus globulus) were obtained from 
Kneading Wellness® with completed gas chromatography from the Department of 
Agriculture and Natural Resources from Delaware State University. Gas chromato-
graphy confirmed that EOs conesponded to the expected natural variation of the oil 
tested with good odor quality. Adulteration was not detected. 
Significance to Nursing 
Nursing agency interfaces SC agency (Orem, 1985). The nurse's role encom-
passes art and science synthesizing knowledge for innovative problem solutions. These 
innovative interventions must function effectively within the individuals' environment to 
endure the challenges within a lived context. Nurses bridge these realities. They assess 
individual knowledge and the ability to partially or completely meet SC requisites. 
Nurses use their unique education, knowledge base, and practice experience to create 
empowering, effective interventions for those with chronic illness within their context 
reality to gain quality of life. 
Experienced RNs should learn about EOs, their safety, indications, applications, 
and efficacy. Schools of nursing should teach students evidence-based practice under the 
rubric of integrative medicine. Academic scholars and nursing researchers should pursue 
the study of herbal medicine, develop instruments, a scientific knowledge repository 
and cost-effective SC interventions for people living with chronic illness. 
Recommendations 
This study completed an initial step in the investigation of AT's feasibility and 
effectiveness in the SC of a middle-aged female with FM. This CSR established a 
baseline for other researchers to build upon in examining the feasibility and effectiveness 
of such approaches. 
The perceptions of individuals with chronic illness seems to be pivotal in SC 
mangement. Self-perceptions help facilitate the creation and implementation of SCI. 
Consistent, successful use of interventions form the framework for effective SC manage-
ment. Therefore, it is recommended that psychoneuroimmunology be explored as a 
theoretical framework for further studies. 
Recommendations include further VAS tool testing and modifications. A tool 
exploring the efficacy of EOs compared to function, ADL, and IADL also needs develop-
ment and testing. Both qualitative and quantitative research is needed for SCIs using 
EOs for chronic illness. Studies need medicinal grade EOs with gas chromatography for 
EO verification. 
Methodologically, recommendations include the researcher asking the VAS 
questions rather than the informant(s) writing answers since this behavior can elicit pain. 
Quality nanative can be added during this process, therefore, audio taping may be advise-
able. Further considerations include frequent breaks for the informant's personal needs 
and/or dividing VAS testing into multiple data collection dates. Data collection needs to 
be flexible enough to accommodate the informant's health care needs and comfort. 
Limitations 
This CSR glimpsed the contextual, multidimensional reality of living with FM 
from one informant's perspective. It captured the brutal truth of living with limitations 
imposed by FM symptoms with the comorbidity of OA. Data conveyed daily struggles 
and SCIs to control daily FM symptom fluctuations. Sensitively, it nanates the story of 
one person, therefore, findings cannot be extrapolated and applied for larger populations. 
Yin (2009, p. 15), however, argues that "case studies, like experiments, are generalizable 
to theoretical propositions and not to populations or universes". Therefore, this CSR 
supports the application of Dorothy Orem's (1985) self-care deficit theory and the 
principles of integrative medicine (Maizes, et al, 2009) in research studies of FM. 
Conclusions 
This CSR answered 4 questions related to how and why: (1) the informant used 
EOs in SC; (2) multimodal approaches managed S & S of FM; (3) EOs helped the 
informant maintain function and ADLs; (4) the informant integrated SCM with EOs, their 
use, effects and outcome into the context of her daily life. Data were analyzed froml 1 
rheumatologic MRs/visits, 4 VAS tools, literature reviews, and an indepth interview. 
These were supplemented with the researcher's field observations and notes for further 
clarification. 
The theoretical framework used was Orem's (1985) self-care deficit supported by 
the principles of IM. Data supported the integration of SCD and IM as well as their con-
gruency to the informant's philosophy of care. Additionally, the MR and interview pro-
vided further confirmation that the principles of IM were reinforced and supported by 
health care team members. 
Yin's (2009) methods were used to establish internal and external validity as well 
as reliability. Triangulation of data occurred and supported conclusions involving SCD, 
SCI, SCM, and IM using EOs to support FM symptom management. 
The diagnosis of FM was one of exclusion. Approaches to FM were multimodal. 
The informant used meloxicam, chiropractic treatments, vitamins, diet modifications, and 
EOs to maintain her health. She fried acupuncture but determined that it was not effec-
tive. Meloxicam managed her generalized FM pain and discomfort. Chiropractic treat-
ments managed her skeletal misalignments which predated her FM diagnosis. Vitamins 
were used as dietary supplements including fluctuating vitamin D doses for an identified 
deficiency. Diet modifications were made to manage the gastroesophageal reflux possi-
bly related to the continued use of meloxicam. EOs were used to control daily fluctua-
tions of FM symptoms. 
Essential oils were used to treat FM pain at trigger points, especially for HAs, 
shoulders, arms and other areas she could reach for M/S discomfort. Using a 10 point 
Likert VAS scale, EOs were significantly effective (7-10) to manage 6 of 29 FM symp-
toms: nasal congestion, runny nose, muscular HAs, neck pain, shoulder and/or upper 
back pain/discomfort, and problems sleeping. Essential oils were moderately effective 
(4-6.5) in treating 5 other symptoms: sinus congestion, sinus HAs, generalized M/S 
pain/discomfort, increased sensitivity to touch, and knee pain. One symptom, heel pain, 
was minimally managed by the application of EOs. Sandi used EOs once on her hip pain 
with a 3 out of 10 rating, This was not included in the report of "routine" symptoms 
treated with EOs. The informant did not use EOs on 16 symptoms since she did not 
know they were related to FM symptoms. 
The informant's best self-reported FM symptom management was through the use 
of undiluted EOs. Oils related to the control of her FM symptoms were the focus of the 
literature review. Studies were previously cited in the literature review (Chapter 2). In 
summary, the literature review on the properties of the informant's selected undiluted 
essential oils supported her use and essential oil efficacy to relieve FM symptoms. 
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The informant found that EOs relieved symptoms faster than oral drugs. Diluted 
EO mixes were used in the work setting so that they would not offend others. Diluted EO 
transdermal efficacy was achieved when applied/reapplied as needed early for symptom 
management. Undiluted, neat, layered EO applications were sfronger and more effective 
than diluted mixes. Applications of undiluted transdermal EOs occuned in the home set-
ting after work and before sleep for pain resolution, improved breathing and relaxation. 
Pharmacologic agents were decreased or eliminated with the use of EOs including anti-
histamines, analgesics, and decongestants. 
Sandi reported that living with FM is frustrating 100% of the time. She took 
personal accountability making daily decisions to manage pain (with a high tolerance 
level), teach, participate in school activities, socialize and continue her life. The infor-
mant narrated her journey of learning to manage FM cautioning healthcare providers that 
they are respectful consultants, not decision makers. 
The SC use of EOs for this informant is best captured in her following nanative: 
The oils treat my pain which keeps me from doing what I want to do. Oils help 
alleviate my pain so I can do what I want to do, when I want to do it. If I can 
live my life the way I want, I'm not as frustrated and angry. I'm trying to control 
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Aromatherapy Massage Research 
Aim, Purpose & 
Method 
Standardized 1 hr 




(HADS) prior to 1st 
& last massage. 
VAS pre/post 
massage. 8 mo. 
study. 
Search retrieved 
1322 references. 10 
met inclusion criteria 
representing 8 RCTs. 
Psychological & 
immunologic 
parameters in open 
semi-comparative 
trial using State Trait 
Anxiety Inventory 
(STAI) test & 
HADS. Data 
collected 1 mo. 
pre/post before & 
after 1st, 5th, & 8th 
30 min AT massage 
2 x/wk for 4 wks. 
Weekly massage 
w/wo EO x 4 wks. 












N = 8 






















HADS scores & 







EOs might f 
anxiety in cancer 
patients short 
term; insufficient 
data for firm 
conclusion. 
Anxiety J. in 1-30 
min AT massage 
in STAI test. 1 in 
8 sequential AT 
massage sessions 
in HADS test. 
Results suggest 




strate long term 
benefit of AT of 
massage to im-
prove pain, Anxi-
ety, or QOL. 
Sleep scores 
improved in both 
groups. Suggest 
patient with high 
psychological dis-





















RESEARCH ON ESSENTIAL OILS' PHYSIOLOGICAL EFFECTS 
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Research on Essential Oils' Physiological Effects 
Aim, Purpose & 
Method 
Verify effects of AT 
massage on consti-
pation. RCT pretest/ 
posttest design w 
placebo. Constipa-
tion Assessment 
Scale (CAS) & # if 
BMs/wk x 10 days. 
Data analysis: 
ANOVA 
Evaluate use of AT 
to I anxiety prior 
colonoscopy or 
esophogastroduoden-
oscopy. STAI pretest 
/posttest. Controlled, 
prospective study w 
convenience sample. 
Effect of foot-bath 
w/wo EO on ANS. 
RCT crossover. 
Measured outcomes: 
EKG, finger tip 
blood flow evaluated 
using spectral 
analysis: HR, RR 
Double study using 
placebo, EO, 
Dimenhydrinate w 



























fects of AT lasted 
2 wks post freat-
ment. Findings 
suggest that AT 
helps relieve 
constipation. 
Pre STAI raw 
scores: 99th $ & 
96th S percentiles 
for anxiety. 




No change in HR, 





10 min w/wo EO. 
Ingestion of lGm 
ginger root pretest 
were able to toler 
ate motion 
several moments 
longer wo N/V 
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PRINCIPLES OF INTEGRATIVE MEDICINE 
Maizes, V., Rakel, D., Niemiec, C. (2009), pp. 6-8. 
1. Patient and Practitioner are parners in the healing process. 
2. All factors that influence health, wellness, and disease are taken into 
consideration, including mind, spirit, and community, as well as body. 
3. Appropriate use of both conventional and alternative methods 
facilitates the body's innate healing response. 
4. Effective interventions that are natural and less invasive should be 
used whenever possible. 
5. Good medicine is based in good sciences. It is inquiry-driven and 
open to new paradigms. 
6. Ultimately, the patient must decide how to proceed with treatment 
based on values, beliefs, and available evidence. 
7. Alongside the concept of treatment, the broader concepts of health 
promotion and the prevention of illness are paramount. 
8. Practitioners of integrative medicine should exemplify its principles 





University of San Diego 
Institutional Review Board 
Research Participant Consent Form 
For the research study entitled: 
"Fibromyalgia Self-Care Management: Use of Essential Oils" 
I. Purpose of the research study 
Regina Izu is a doctoral student in the Hahn School of Nursing at the University 
of San Diego. You are invited to participate in a research study she is 
conducting. The purpose of this research study is to look at how people who 
have fibromyalgia use essential oils to help their symptoms and what that's like 
for them. 
II. What you will be asked to do 
If you decide to be in this study, you will be asked to: 
1) Meet with me twice at a location and time convenient to you, where privacy 
can be assured. During the first meeting, you will complete four questionnaires 
that ask you questions about how severe and frequent your fibromyalgia 
symptoms are, how well you are able to function and perform activities of daily 
living, and how effective using essential oils has been for your fibromyalgia 
symptoms. This will take about an hour. 
2) At the second meeting about a week later, you will participate in a private 
interview about your experience of using essential oils for your fibromyalgia, and 
what that's been like for you. You will be audiotaped during the interview. This 
will take about an hour and a half. 
Your participation in this study will take about a total of 2 hours and 30 minutes. 
III. Foreseeable risks or discomforts 
Sometimes when people are asked to think about their feelings about a health 
concern like fibromyalgia, they feel sad or anxious. If you would like to talk to 
someone about your feelings at any time, you can call toll-free, 24 hours a day: 
San Diego Mental Health Hotline at 1-800-479-3339 
Another risk is that you might feel fatigued while filling out the questionnaires and 
doing the interview. You can stop and rest at any time. You can re-schedule our 
meeting(s), or you can decide to quit altogether. 
IV. Benefits 
While there may be no direct benefit to you from participating in this study, the 
indirect benefit of participating will be in knowing that you helped researchers 
better understand how people with fibromyalgia use essential oils. 
V. Confidentiality 
Any information provided and/or identifying records will remain confidential and 
kept in a locked file and/or password-protected computer file in the researcher's 
office for a minimum of five years. All data collected from you will be coded with a 
number or pseudonym (fake name). Your real name will not be used. The results 
of this research project may be made public and information quoted in 
professional journals and meetings, but information from this study will only be 
reported as a group, and not individually. 
VI. Compensation 
You will receive no compensation for your participation in the study. 
VII. Voluntary Nature of this Research 
Participation in this study is entirely voluntary. You do not have to do this, 
and you can refuse to answer any question or quit at any time. Deciding not to 
participate or not answering any of the questions will have no effect on any 
benefits you're entitled to, like your health care, employment, or any other social 
services. You can withdraw from this study at any time without penalty. 
VIII. Contact Information 
If you have any questions about this research, you may contact either: 
1) Regina Izu 
Email: rizu@sandiego.edu 
Phone: 619-260-4196 
2) Dr. Jane Georges 
Email: jgeorges@sandiego.edu 
Phone: (619) 260-4566 
I have read and understand this form, and consent to the research it 
describes to me. I have received a copy of this consent form for my 
records. 
Signature of Participant Date 
Name of Participant (Printed) 
Signature of Investigator Dat 
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Research ID: 
Chronic Symptom Frequency Scale 
Date: 
Directions: Please circle the number which best answers how frequently you 
experience a symptom within a 24 hour day related to your chronic 
conditions of rhinitis (nasal breathing conditions) and fibromyalgia (fatigue 
and sore muscles). You may write additional brief comments under the 
question. 
Answer Key: How often do you experience these symptoms on a daily basis 
(24 hour)? 
0 = inconsistently, not experienced on a daily basis. 
1 = 10% of the time 
2 = 20% of the time 
3 = 30% of the time 
4 = 40% of the time 
5 = 50% of the time 
6 = 60% of the time 
7 = 70% of the time 
8 = 80% of the time 
9 = 90% of the time 
10 =100% of the time 
1. I have nasal congestion. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
2. I have sinus congestion. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
3. I have a runny nose. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
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4. I have teary eyes. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
5. I have sinus headaches. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
6. I have muscular headaches. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
7. I have trouble concentrating (thinking). 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
8. I have jaw pain. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
9. I have neck pain. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
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10. I have generalized musculoskeletal pain and discomfort. 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
11. Exposure to cold makes my pain worse. 
1) I 2 3 4 5 6 7 8 9 10 
Comment: 
12. My body feels like it is stiff. 
_ _ _ _ _ _ _ _ _ _ _ 
Comment: 
13. I have morning fatigue (tiredness). 
_ _ _ _ _ _ _ _ _ _ _ 
Comment: 
14. I have generalized fatigue (tiredness). 
__ _ _ _ _ _ _ _ _ _ _ 
Comment: 
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15. I have increased sensitivity to touch. 
~0 1 2 3 4 5 6 7 8 9 10 
Comment: 
16.1 have shoulder and/or upper back pain/discomfort. 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
17. I have chest pain, discomfort, and/or heaviness (noncardiac). 
~0 I 2~~ 3 4 5 6 7 8 9 10 
Comment: 
18. I have lower back pain. 
~0 I 2 3 4~ 5~ 6 7 8 9 10 
Comment: 
19. I have hip pain. 
~0 1 2 3 4 5 6 7 8 9 10 
Comment: 
20. I have knee pain. 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
21. I have heel pain. 
~0 1 2 3 4 5 6 7 8 9 10 
Comment: 
22. I have irregular bowel problems. 
~0 1 2 3 4 5 6 7 8 9 10 
Comment: 
23. I have problems sleeping. 
~0 1 2 3 4 5 6 7 8 9 10 
Comment: 
24. I have feelings of anxiety related to my symptoms or diagnosis. 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
25.1 have felt overwhelmed by my symptoms. 
1) 1~ 2 3 4 5 6 1 8 9 10 
Comment: 
26. I have feelings of sadness related to living with fibromyalgia. 
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0 1 2 3 4 5 6 7 8 9 10 
Comment: 
27. I have suffered from my symptoms related to fibromyalgia. 
~0 1 2 3 4 5 6 7 8 9 10 
Comment: 
28. I have felt frustrated because of living with fibromyalgia. 
1) 1 2 3 4 5 6 T ~8 9 10 
Comment: 
29. I have felt angry because of living with fibromyalgia. 




Chronic Symptom Severity Scale 
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Research ID: 
Chronic Symptom Severity Scale 
Date: 
Directions: Please circle the number which best answers the usual severity 
of the symptom you experience related to your chronic condition of 
fibromyalgia (fatigue and sore muscles). You may write additional brief 
comments under the question. 
Answer Key: How often do you experience these symptoms on a daily basis 
(24 hour)? 
0 = No symptom experienced 
1 = Barely Noticeable 
2 = Very Minimal 
3 = Minimal 
4 = Bothersome 
5 = Moderate discomfort 
1. I have nasal congestion. 
6 = Increasing Moderate Discomfort 
7 = Moderately Severe, Discomfort 
8 = Increasing Intensity and Discomfort 
9 = Severe, Consistent Discomfort 
10 = Worse Severity Imaginable 
0 1 8 10 
Comment: 
2. I have sinus congestion. 
0 8 10 
Comment: 
3. I have a runny nose. 
0 8 10 
Comment: 
4. I have teary eyes. 
~0 I 2~ 3 4 5 6 7 8 9 10 
Comment: 
5. I have sinus headaches. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
6. I have muscular headaches. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
7. I have trouble concentrating (thinking). 
1) I 2 3 4 5 6 ~7 8 9 10 
Comment: 
8. I have jaw pain. 
~0 1 2 3 4 5 6 7 8 9 10 
Comment: 
9. I have neck pain. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
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10. I have generalized musculoskeletal pain and discomfort. 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
11. Exposure to cold makes my pain worse. 
_ _ _ _ _ _ _ _ _ _ _ 
Comment: 
12. My body feels like it is stiff. 
~0 I 2 31 4 5 6 7 8 9 10 
Comment: 
13. I have morning fatigue (tiredness). 
1) I 2 3 4 5 6 7 8 9 10 
Comment: 
14. I have generalized fatigue (tiredness). 
__ _ _ _ _ _ _ _ _ _ _ _ 
Comment: 
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15. I have increased sensitivity to touch. 
1) I 2 3 4 5 6 7 8 9 10 
Comment: 
16. I have shoulder and/or upper back pain/discomfort. 
~0 I 2 3 4~ 5 6 7 8 9 10 
Comment: 
17.1 have chest pain, discomfort, and/or heaviness (noncardiac). 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
18. I have lower back pain. 
~0 I 2 3 4~ 5~ 6 7 8 ~9 10 
Comment: 
19. I have hip pain. 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
20. I have knee pain. 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
21. I have heel pain. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
22. I have irregular bowel problems. 
~0 1~ 2 3 4 5 6 7 8 9 10 
Comment: 
23. I have problems sleeping. 
_ _ _ _ _ _ _ _ _ _ _ _ 
Comment: 
24. I have feelings of anxiety related to my symptoms or diagnosis. 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
25.1 have felt overwhelmed by my symptoms. 
__ _ _ _ _ _ _ _ _ _ _ _ 
Comment: 
26. I have feelings of sadness related to living with fibromyalgia. 
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0 1 2 3 4 5 6 7 8 9 10 
Comment: 
27. I have suffered from my symptoms related to fibromyalgia. 
1) I 2 3 4 5 6 7 8 9 10 
Comment: 
28. I have felt frustrated because of living with fibromyalgia. 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
29. I have felt angry because of living with fibromyalgia. 




FUNCTION AND ACTIVITIES OF DAILY LIVING SCALE 
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Function and Activities of Daily Living Scale 
Research ID: Date: 
Directions: Please circle the number which best answers how symptoms 
related to your chronic condition of fibromyalgia interfere with your 
activities of daily living and functional status. You may write additional 
brief comments under the question. 
Answer Key: How do your symptoms impact your daily life in the following 
activities and functions? 
0 = No Interference 
1 = Barely Noticeable Interference 6 = Increasingly Moderate Interference 
2 = Very Minimal Interference 7 = Moderately Severe Interference 
3 = Minimal Interference 8 = Increasing and Intense Interference 
4 = Bothersome Interference 9 = Severe and/or Consistent Interference 
5 = Moderate interference 10 = Worse Imaginable Interference 
1. Personal daily hygiene activities (bathing, dressing, brushing hair and 
teeth, etc.) 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
2. Cooking. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
3. Cleaning and/or 
0 1 2 
complete housework activities. 
3 4 5 6 7 8 9 10 
Comment: 
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4. Complete repetitive actions. 
_ _ _ _ _ _ _ _ _ _ _ 
Comment: 
5. Gardening, doing outside chores, and/or hobbies. 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
6. Driving. 
0 1 2 i5 4 5 6~ 7 8 9 10 
Comment: 
7. Shopping. 
"() 1 2 3 4 5̂  6 7̂  8 9 10 
Comment: 
8. Caring for others (friends, family, and pets). 
__ _ _ _ _ _ _ _ _ _ _ _ _ 
Comment: 
9. Completing work and job role expectations. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
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10. Energy to complete job and/or work related expectations. 
T ~ I 2 3 4 5 6 7 8 9 10 
Comment: 
11. Energy to go out with others to socialize. 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
12. Walking. 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
13. Running, jogging and/or exercising. 
I* I 2 3 4 5 6 7 8 ~~9 10 
Comment: 
14. Lifting objects. 
Is I 2 3 4 5 6 7 8 <T 10 
Comment: 
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15. Pulling objects. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
16. Pushing objects. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
17. Grasping and holding on to objects. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
18. Carrying objects. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
19. Joint and muscle flexibility (range of motion). 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
20. Maintaining balance. 




~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
22. Organizing your daily activities or what you do each day. 
~0 ~1 2 3 4~ 5 6 7 8 9 10 
Comments: 
23. Organizing your social calendar and activities. 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
24. Eating patterns. 
1) 1 2 3 4 5 6 7 8 9 10 
Comment: 
25. Sleeping patterns. 
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Essential Oil Efficacy Scale 
Research ID: Date: 
Directions: Please circle the number which best answers how essential oils 
affect your experiences and symptoms related to fibromyalgia. You may 
write additional brief comments under the question. Please put N/A under 
comments if you do NOT experience symptom. 
Answer Key: When I use essential oils there is: 
0 = No Difference/Improvement 
1 = Barely Noticeable Difference/Improvement 
2 = Very Minimal Difference/Improvement 
3 = Minimal Difference/Improvement 
4 = More than Minimal Difference/Improvement 
5 = Moderate Difference/Improvement 
6 = Moderate Plus Difference/ Improvement 
7 = Significant Difference/Improvement 
8 = Significant Plus Difference/Improvement 
9 = Remarkable, Consistent Difference/Improvement 
10 = Best Difference/Improvement Imaginable 
1. in my nasal congestion. 
0 1 8 10 
Comment: 
2. in my sinus congestion. 
0 8 10 
Comment: 
3. in my runny nose. 
0 1 8 10 
Comment: 
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4. in my teary eyes. 
Is I 2 3 4 5 6 7 8~~ 9 10 
Comment: 
5. in my sinus headaches. 
T 1 2 3 4 5 6 7 8 9 10 
Comment: 
6. in my muscular headaches. 
~0 1 2 3 4 5 6 7 8~ ~ 9 10 
Comment: 
7. in my trouble concentrating (thinking). 
Is I 2 3 4 5 6 7 8 9 10 
Comment: 
8. in my jaw pain. 
~0 1 2 3~ 4 5 6 7 8 9 10 
Comment: 
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9. in my neck pain. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
10. in my musculoskeletal pain and discomfort. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
11. in the feeling that cold makes my pain worse. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
12. in my body feeling stiff. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
13. in my morning fatigue (tiredness). 
0 1 2 3 4 5 6 7 8 9 10 
Comment: ^^m^^_^^^mmm^^^^^^m^, 
14. in my generalized fatigue (tiredness). 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
15. in my increased sensitivity to touch. 
"0 1 2 3 4 5 6 7 8 9 10 
Comment: 
16. in my shoulder and/or upper back pain/discomfort. 
_ _ _ _ _ _ _ _ _ _ _ 
Comment: 
17. in my chest pain, discomfort, and/or heaviness (noncardiac). 
"0 I 2 3 4 5 6 7 8 9 10 
Comment: 
18. in my lower back pain. 
_ _ _ _ _ _ _ _ _ _ _ _ 
Comment: 
19. in my hip pain. 
"() 1 2 3 4 5 6 7 8 9 10 
Comment: 
20. in my knee pain. 
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0 1 2 3 4 5 6 7 8 9 10 
Comment: 
21. in my heel pain. 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
22. in my irregular bowel problems. 
1) 1 2 3 4 5 6 7 8 9 10 
Comment: 
23. in my problems sleeping. 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
24. in my feelings of anxiety related to my symptoms or diagnosis. 
~0 I Y "3 4 5 6 7 8 9 10 
Comment: 
25. in my feeling of becoming overwhelmed by my symptoms. 
0 1 2 3 4 5 6 7 8 9 10 
Comment: 
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26. in my feelings of sadness related to living with fibromyalgia. 
_ _ _ _ _ _ _ _ _ _ _ 
Comment: 
27. in my feelings of suffering from my symptoms related to 
fibromyalgia. 
"0 I 2 3 4 5̂  6 7 8 9 10 
Comment: 
28. in my feelings of frustration because of living with fibromyalgia. 
~0 I 2 3 4 5 6 7 8 9 10 
Comment: 
29. in my feelings of anger because of living with fibromyalgia. 
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Indepth Interview Questions 
Interview questions may include, but not be limited to the following: 
Inception of Self-Care Practice 
1. How did you manage your chronic condition symptoms before your medical 
diagnosis and treatment? 
2. How long ago were you diagnosed with fibromyalgia? 
3. Why did you seek medical care? 
4. How did you feel after receiving the medical diagnosis of fibromyalgia? 
5. How did your medical physician decide on your plan(s) of care for your chronic 
conditions? 
6. How did the doctor explain your treatment/medications to you? 
7. Why did you decide to try treatment other than the physician's medical 
prescription(s)? 
8. How did this original medical diagnosis affect your QOL? 
9. How did you learn about treatments other than medical interventions? 
10. How did you learn about essential oils and their affects? 
11. Why did you decide to try essential oils? 
12. How did you obtain the EOs at this stage? 
13. How did you mix the EOs and decide which ones to use? 
14. How did you store the EOs? 
15. How did the EOs affect you? 
16. How often did you use the EOs? 
17. How much of the EOs (dose) did you use? Whys did you choose this dose? 
18. How did you apply the EOs and where did you apply them? 
19. Why did you choose to use this much oil and apply it the way you did? 
20. How did you feel when you used the EOs? 
21. How did you feel when you didn't use the EOs? 
22. Why did you continue to use the EOs? 
23. How did your physician react to your use of EOs? 
24. How did the addition of EOs affect your medically prescribed treatment? 
25. Why did you make the choice to try different health care interventions to control 
your symptoms of chronic conditions? 
26. How often did you get colds or illness after you started using EOs? 
Self-Care Practice: Midpoint 
1. Why did you continue to use EOs? 
2. How did the use of EOs fit into your lifestyle? 
3. How did EOs affect your symptoms from chronic conditions? 
4. How has your medical care changed? (Medications, treatments) 
5. How did your physician react to your continued use of EOs? 
6. How did the continued use of EOs affect your drug doses (OTC or prescribed?) 
7. How did you maintain your highest level of functioning? 
8. How did you feel when you did or didn't use the EOs? 
9. How did you obtain the oils? 
10. How did you store the oils? 
11. How did you use the EOs, singly? Combined? For different symptoms? 
12. How did you mix the EOs? 
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13. Why did you choose particular EOs to use? 
14. How and why did you choose the EO doses, frequency, application, and 
locations? 
15. How did your symptoms respond to the use of EOs? 
16. Why do you feel your disease has or has not improved? 
17. How often did you get colds or illness after you started using EOs? 
Currently Lived Self-Care Experience 
1. How long have you been using EOs? 
2. How have your changed which EOs you use from the beginning of your use to 
now? 
3. Why did you make those changes? 
4. How have you changed the dose, frequency, application, and/or locations EO use? 
5. Why did you make those changes? 
6. How are you obtaining your EOs? 
7. How do you mix your EOs? 
8. Why do you mix them the way that you do? 
9. How do you store your EOs? Why do you store them that way? 
10. Why do you continue to use EOs? 
11. How does your physician feel about your continued use of EOs? 
12. How has the use of EOs been adapted into your lifestyle? 
13. Why would you continue to use EOs as a self-care management intervention? 
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DILUTED RESPIRATORY BLENDS 
PREVIOUS SINUS BLEND DURING UPPER RESPIRATORY INFECTION 
(Resolved without antibiotics and/or antivirals. Original blend by Sandi's sister) 
Tea Tree (Malaleuca alternifolia) 15 gtts 
Peppermint (Mentha x piperita) 15 gtts 
Rose Otto (Rosa damascena) 3 gtts 
Eucalyptus (Eucalyptus radiata) 36 gtts 
Eucalyptus (Eucalyptus globulus) 7 gtts 
Eucalyptus (Eucalyptus citradora) 10 gtts 
Spikenard (Nardostachys jatamansi) 2 gtts 
Hyssop (Hyssopus officinalis) 5 gtts 
Thyme (Thymus vulgaris) 7 gtts 
Mandarin Red (Citrus reticulata) 10 gtts 
Mandarin Green (Citrus reticulata bianco) 10 gtts 
Sage (Salvia officinalis) 12 gtts 
Myrtle (Myrus communis) 10 gtts 
Ravinsara (Cinnamomum camphor a) 12 gtts 
SELF-MIXED SINUS BLEND 
10/24/10 mixed in a 10 mL amber bottle 
Tea Tree (Malaleuca alternifolia) 15 gtts 
Peppermint (Mentha x piperita) 20 gtts 
Eucalyptus (Eucalyptus globulus) 25 gtts 
Ravinsara (Cinnamomum camphor a) 12 gt 
